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“…The	   so-­‐called	   ‘psychotically	   depressed’	   person	  who	   tries	   to	   kill	   herself	   doesn't	   do	   so	  
out	  of	  quote	  ‘hopelessness’	  or	  any	  abstract	  conviction	  that	  life's	  assets	  and	  debits	  do	  not	  
square.	  And	  surely	  not	  because	  death	  seems	  suddenly	  appealing.	  The	  person	  in	  whom	  Its	  
invisible	   agony	   reaches	   a	   certain	   unendurable	   level	   will	   kill	   herself	   the	   same	   way	   a	  
trapped	  person	  will	   eventually	   jump	   from	   the	  window	  of	  a	  burning	  high-­‐rise.	  Make	  no	  
mistake	   about	   people	   who	   leap	   from	   burning	   windows.	   Their	   terror	   of	   falling	   from	   a	  
great	  height	   is	  still	   just	  as	  great	  as	   it	  would	  be	   for	  you	  or	  me	  standing	  speculatively	  at	  
the	  same	  window	  just	  checking	  out	  the	  view;	  i.e.	  the	  fear	  of	  falling	  remains	  a	  constant.	  
The	  variable	  here	  is	  the	  other	  terror,	  the	  fire's	  flames:	  when	  the	  flames	  get	  close	  enough,	  
falling	  to	  death	  becomes	  the	  slightly	  less	  terrible	  of	  two	  terrors.	  It's	  not	  desiring	  the	  fall;	  
it's	  terror	  of	  the	  flame	  yet	  nobody	  down	  on	  the	  sidewalk,	  looking	  up	  and	  yelling	  ‘Don‘t!’	  
and	  ‘Hang	  on!’,	  can	  understand	  the	  jump.	  Not	  really.	  You'd	  have	  to	  have	  personally	  been	  
trapped	  and	  felt	  flames	  to	  really	  understand	  a	  terror	  way	  beyond	  falling…”	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BACKGROUND:	   schizophrenic	   and	   bipolar	   disorders	   are	   complex	   and	   disabling	  
psychiatric	  diseases	  whose	  classical	  nosography	  and	  classification	  are	  still	  under	  
challenging	  debate	  aiming	  to	  overcome	  the	  traditional	  “Kraepelinian	  Dichotomy”.	  
For	   the	   past	   hundred	   years	   most	   clinical	   work	   and	   research	   in	   psychiatry	   has	  
proceeded	   under	   the	   assumption	   that	   schizophrenia	   and	   bipolar	  
disorder	  are	  distinct	  entities	   with	   separate	   underlying	   disease	   processes	   and	  
treatments.	   In	   more	   recent	   years	   there	   has	   been	   increasing	   evidence	   for	  
phenomenological,	   biological	   and	   genetic	   overlap	   between	   the	   two	   disorders	  
(Potash	  and	  Bienvenu	  2009).	  Nowadays,	  the	  categorical	  approach	  to	  psychiatric	  
nosography	   is	   in	   contrast	   with	   the	   recent	   neurobiological,	   neuropsychological	  
and	  genetic	  findings	  in	  affective	  and	  schizophrenic	  disorders.	  Further,	  symptoms	  
and	  signs	  constituting	  bipolar	  and	  schizophrenic	  disorders	  are	  continuously,	  not	  
dichotomously,	  distributed;	  there	  may	  be	  no	  point	  of	  “real	  cleavage”	  (Phelps	  et	  
al.	   2008).	   This	   recognition	  has	   led	   some	  clinicians	   and	   researchers	   to	   call	   for	   a	  
diagnostic	   model	   that,	   moving	   to	   a	   “dimensional	   perspective”,	   formally	  
recognizes	  a	  continuous	  spectrum	  from	  schizophrenic	   to	  bipolar	   (and	  recurrent	  
depressive)	  disorders.	  Kelsoe	  argued	  that	  the	  existing	  data	  coming	  from	  various	  
fields	  of	  research	  in	  bipolar	  and	  schizophrenic	  disorders	  may	  best	  fit	  a	  model	  in	  
which	   different	   set	   of	   genes	   predispose	   to	   overlapping	   phenotypes	   in	   a	  
continuum.	  Given	  the	  apparent	  overlap	  of	  regions	  of	   the	  genome	   implicated	   in	  
bipolar	  disorder	  with	  those	  for	  schizophrenia	  (Kelsoe	  1999;	  Berrettini	  2000),	  the	  
data	  suggest	  the	  possibility	  that	  a	  common	  polygenic	  background	  predisposes	  to	  
both	   bipolar	   disorder	   and	   schizophrenia,	   according	   to	   the	   so-­‐called	   “multiple	  
threshold	   model”	   (Kelsoe	   2003).	   As	   highlighted	   by	   Craddock	   and	   Owen,	   the	  
recent	   findings	   are	   compatible	   with	   a	   model	   of	   functional	   psychosis	   in	   which	  
susceptibility	   to	   a	   spectrum	   of	   clinical	   phenotypes	   is	   under	   the	   influence	   of	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overlapping	   sets	   of	   genes,	   which,	   together	  with	   environmental	   and	   epigenetic	  
factors,	   determine	   an	   individual’s	   expression	   of	   illness	   (Craddock	   and	   Owen	  
2005).	  A	   lot	  of	   interest	   is	   focusing	  on	  brain	   structural	  abnormalities	   in	  patients	  
suffering	   from	   schizophrenia	   and	   bipolar	   disorder.	   A	   huge	   amount	   of	  
neuroimaging	   studies	   has	   been	   published	   so	   far,	   however	   the	   literature	   is	  
heterogeneous	  and	  there	  is	  still	  some	  degree	  of	  uncertainty	  concerning	  what	  key	  
regions	   are	   involved	   in	   the	   pathogenesis	   of	   such	   disorders.	   Schizophrenia	   and	  
Bipolar	  Disorder	  have	  a	  number	  of	  overlapping	  symptoms	  and	  risk	  factors,	  but	  it	  
is	   not	   yet	   clear	   if	   the	  disorders	   are	   characterized	  by	   similar	  deviations	   in	  brain	  
morphometry	   or	   whether	   any	   such	   deviations	   reflect	   the	   impact	   of	   shared	  
susceptibility	   genes	   on	   brain	   structure.	   To	   date	   there	   is	   no	   consensus	   about	  
whether,	   and	   to	  what	   extent,	   gray	  matter	   loss	   in	   Schizophrenia	   is	  mirrored	   in	  
Bipolar	   Disorder	   and	   what	   is	   the	   effect	   of	   medication	   or	   other	   confounding	  
factors.	  Studies	  in	  family	  members	  of	  patients,	  who	  share	  the	  risk	  of	  the	  disease	  
but	   not	   the	   confounding	   factors,	  may	   help	   elucidate	  whether	   abnormalities	   in	  
brain	  structures	  are	  shared	  by	  both	  illnesses.	  
	  
AIM	  OF	  THE	  STUDY:	  to	  investigate	  hippocampal	  gray	  matter	  volume	  differences	  
in	  a	  group	  of	  patients	  with	  bipolar-­‐schizophrenic	  spectrum	  disorders,	  a	  group	  of	  
their	  unaffected	  first-­‐degree	  relatives,	  and	  a	  group	  of	  healthy	  control	  subjects.	  
	  
METHODS:	  a	   total	  of	  104	  subjects	   -­‐	  36	  schizophrenic	  or	  schizoaffective	   (SZ),	  27	  
bipolar	   (BP),	   2	   major	   depression,	   8	   unaffected	   relatives	   (UR),	   and	   31	   healthy	  
controls	  (HC)	  -­‐	  underwent	  1,5	  T	  MRI	  scanning,	  with	  volumetric	  T1	  3D	  acquisition	  
protocol,	   at	   the	   Neuroradiology	   Unit	   of	   Conegliano	   Hospital.	   We	   calculate	  
bilateral	  hippocampal	  gray	  matter	  volume	  (HV)	  and	  total	  cerebral	  volume	  (TCV)	  
in	  a	  sample	  of	  31	  SZ,	  27	  BP,	  8	  UR	  and	  26	  HC,	  with	  a	  stereological	  method	  using	  
ANALYZE	  10.0	  software.	  
	  
RESULTS:	  we	  found	  statistically	  significant	  reductions	  in	  bilateral	  HV	  in	  the	  BP-­‐SZ	  
patients	   compared	   to	   HC;	   the	   direct	   comparison	   between	   patient	   groups	  
	   III	  
identified	  statistically	  significant	  reduction	  in	  the	  right	  HV	  of	  SZ,	  but	  no	  significant	  
differences	   for	   left	   HV	   or	   TCV	   (however	   statistical	   significance	   was	   lost	   after	  
normalization);	   statistically	   significant	   reduction	   in	   the	   left	   HV	   and	   a	   trend	  
towards	   statistical	   significance	   for	   right	  HV	   in	   the	  UR	  compared	   to	  HC	   (a	   trend	  
towards	   statistically	   significant	   reduction	   in	   bilateral	   HV	   persisted	   after	  
normalization).	  
	  
CONCLUSION:	   it	   might	   be	   speculated	   that	   the	   alterations	   of	   the	   gray	   matter	  
volume	   in	   the	  hippocampus	  highlighted	   in	  our	   study	   could	  be	   interpreted	  as	   a	  
possible	  structural	  “biological	  marker”	  in	  the	  bipolar-­‐schizophrenic	  spectrum.	  
	  IV	  
	  
	   V	  
RIASSUNTO	  
	  
INTRODUZIONE:	   schizofrenia	   e	   disturbo	   bipolare	   sono	   malattie	   psichiatriche	  
complesse	  e	  invalidanti,	   il	  cui	   inquadramento	  nosografico	  è	  oggetto	  di	  continuo	  
dibattito	  nel	  superamento	  della	  classica	  “dicotomia	  Kraepeliniana”	  tra	  Dementia	  
Praecox	   e	   Malattia	   Maniaco-­‐Depressiva.	   Negli	   ultimi	   cento	   anni,	   buona	   parte	  
della	   pratica	   clinica	   e	   della	   ricerca	   in	   psichiatria	   sono	   state	   basate	   sull’assunto	  
che	   schizofrenia	   e	   disturbo	   bipolare	   fossero	   entità	   categorialmente	   distinte,	  
separate	   da	   distinti	   meccanismi	   patologici	   e	   trattamenti.	   In	   anni	   più	   recenti	  
invece,	   si	   sono	   accumulate	   numerose	   evidenze	   a	   supporto	   di	   una	   parziale	  
sovrapposizione	  fenomenologica,	  biologica	  e	  genetica	  tra	  questi	  disturbi	  (Potash	  
e	  Bienvenu	  2009).	  Attualmente,	  l’approccio	  nosografico	  “categoriale”	  nei	  disturbi	  
affettivi	   e	   schizofrenici	   è	   in	   contrasto	   con	   le	   più	   recenti	   scoperte	   in	   ambito	  
neurobiologico,	   neuropsicologico	   e	   genetico.	   Inoltre	   è	   stato	   evidenziato	   come,	  
nemmeno	  dal	  punto	  di	   vista	   clinico	  vi	   sia	  un	   reale	  punto	  di	   “separazione”	   tra	   i	  
due	  disturbi,	  che	  presentano	  segni	  e	  sintomi	  comuni	  e	  sovrapponibili	  (Phelps	  et	  
al.	  2008).	  Tale	  consapevolezza	  ha	  portato	  clinici	  e	  ricercatori	  a	  orientarsi	  verso	  un	  
modello	   diagnostico	   che,	   spostandosi	   in	   una	   prospettiva	   “dimensionale”,	  
formalmente	   riconosce	   l’esistenza	   di	   uno	   spettro	   tra	   disturbi	   schizofrenici	   e	  
bipolari.	  Kelsoe	  afferma	  che	  i	  dati	  provenienti	  dai	  vari	  filoni	  di	  ricerca	  nei	  disturbi	  
bipolari	   e	   schizofrenici	   potrebbero	   essere	  meglio	   spiegati	   da	  un	  modello	   in	   cui	  
differenti	  set	  di	  geni	  predispongono	  a	  fenotipi	  clinici	  che	  si	  sovrappongono	  in	  un	  
continuum.	   Data	   la	   documentata	   sovrapposizione	   fra	   regioni	   genomiche	  
implicate	   nel	   disturbo	   bipolare	   con	   quelle	   della	   schizofrenia	   (Kelsoe	   1999;	  
Berrettini	   2000),	   le	   evidenze	   suggeriscono	   la	   possibilità	   che	   un	   substrato	  
poligenico	   comune	   possa	   conferire	   una	   predisposizione	   a	   entrambi	   i	   disturbi,	  
secondo	   il	   cosiddetto	   modello	   delle	   “soglie	   multiple”	   (Kelsoe	   2003).	   Come	  
sottolineato	   da	   Craddock	   e	   Owen,	   le	   più	   recenti	   scoperte	   in	   tale	   ambito	   sono	  
compatibili	   con	   un	  modello	   	   di	   psicosi	   funzionale,	   nel	   quale	   la	   suscettibilità	   ad	  
uno	  spettro	  di	   fenotipi	  clinici	  è	  sotto	   l’influenza	  di	  un	  set	  di	  geni	  condivisi,	  che,	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insieme	  a	  fattori	  ambientali	  ed	  epigenetici,	  determina	  l’espressione	  di	  malattia	  in	  
ciascun	   individuo	   (Craddock	   e	   Owen	   2005).	   Notevole	   interesse	   si	   sta	   inoltre	  
focalizzando	   sulle	   alterazioni	   strutturali	   cerebrali	   in	   pazienti	   affetti	   da	  
schizofrenia	   e	   disturbo	   bipolare.	   Nonostante	   l’ingente	   mole	   di	   studi	   di	  
neuroimaging	  finora	  pubblicati,	  la	  letteratura	  sull’argomento	  è	  molto	  eterogenea	  
ed	  esiste	  ancora	  notevole	  incertezza	  su	  quali	  siano	  le	  specifiche	  regioni	  cerebrali	  
coinvolte	   nella	   patogenesi	   di	   tali	   disturbi.	   Schizofrenia	   e	   Disturbo	   Bipolare	  
condividono	   una	   serie	   di	   sintomi	   e	   fattori	   di	   rischio,	   ma	   non	   è	   ancora	   stato	  
chiarito	   se	   questi	   disturbi	   siano	   caratterizzati	   da	   comuni	   modificazioni	  
morfometriche	  cerebrali	  e	  se	  tali	  alterazioni	  riflettano	  l’impatto	  di	  geni	  comuni	  di	  
suscettibilità	  sulla	  morfologia	  del	  cervello.	  Ad	  oggi,	  non	  è	  stato	  definitivamente	  
chiarito	   se,	   e	   fino	   a	   che	  punto,	   la	   documentata	  perdita	  di	   sostanza	   grigia	  nella	  
Schizofrenia	  si	  rifletta	  anche	  nel	  Disturbo	  Bipolare	  e	  su	  quali	  siano	  gli	  effetti	  della	  
farmacoterapia	   o	   	   di	   altri	   fattori	   di	   confondimento.	   Gli	   studi	   sui	   membri	   non	  
affetti	   di	   pazienti	   schizofrenici	   e	   bipolari,	   che	   condividono	   la	   predisposizione	  
genetica	   ai	   disturbi,	  ma	  non	   i	   fattori	   di	   confondimento,	   posso	   rivelarsi	   utili	   nel	  
verificare	  se	  le	  varie	  anomalie	  cerebrali	  siano	  condivise	  nelle	  due	  patologie.	  
	  
SCOPO	   DELLO	   STUDIO:	   analizzare	   eventuali	   differenze	   volumetriche	   nella	  
sostanza	   grigia	   ippocampale	   in	   un	   gruppo	   di	   pazienti	   dello	   spettro	   bipolare-­‐
schizofrenico,	   un	   gruppo	  di	   familiari	   di	   primo	  grado	  non	  affetti	   e	   un	   gruppo	  di	  
soggetti	  sani	  di	  controllo.	  
	  
MATERIALI	   E	   METODI:	   un	   totale	   di	   104	   sogetti	   -­‐	   36	   pazienti	   con	   disturbo	  
schizofrenico	   o	   schizoaffettivo	   (SZ),	   27	   pazienti	   con	   disturbo	   bipolare	   (BP),	   2	  
pazienti	   affetti	   da	   depressione	  maggiore	   ricorrente,	   8	   familiari	   di	   primo	   grado	  
non	  affetti	  (UR)	  e	  31	  controlli	  sani	  (HC)	  sono	  stati	  sottoposti	  ad	  una	  procedura	  di	  
Risonanza	   Magnetica	   cerebrale	   ad	   1,5	   Tesla,	   secondo	   un	   protocollo	   di	  
acquisizione	   di	   sequenze	   T1	   3D	   volumetriche,	   presso	   l’Unità	   Operativa	   di	  
Neuroradiologia	   del	   Presidio	  Ospedaliero	   di	   Conegliano.	  Mediante	   l’utilizzo	   del	  
Software	   ANALYZE	   10.0,	   sono	   stati	   calcolati,	   con	   un	   metodo	   stereologico,	   i	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volumi	   bilaterali	   della	   sostanza	   grigia	   ippocampale	   (HV)	   ed	   il	   volume	   cerebrale	  
totale	  (TCV)	  in	  un	  campione	  di	  31	  SZ,	  27	  BP,	  8	  UR	  e	  26	  HC.	  
	  
RISULTATI:	   sono	   state	   riscontrate	   riduzioni	   volumetriche	   statisticamente	  
significative	   della	   sostanza	   grigia	   di	   ippocampo	  destro	   e	   sinistro	   tra	   i	   gruppi	   di	  
pazienti	   dello	   spettro	   bipolare-­‐schizofrenico	   rispetto	   ai	   controlli;	   nel	   confronto	  
diretto	   tra	   il	   gruppo	   di	   pazienti	   schizofrenici	   e	   quello	   dei	   bipolari	   è	   stata	  
identificata	  una	  riduzione	  statisticamente	  significativa	  del	  volume	  della	  sostanza	  
grigia	   dell’ippocampo	   destro	   (tale	   significatività	   non	   persiste	   in	   seguito	   a	  
normalizzazione)	   e	   nessuna	   significativa	   differenza	   nei	   volumi	   della	   sostanza	  
grigia	  dell’ippocampo	  sinistro	  o	  nel	  volume	  cerebrale	  totale;	  nel	  confronto	  tra	  il	  
gruppo	  di	  familiari	  di	  primo	  grado	  non	  affetti	  rispetto	  al	  gruppo	  di	  soggetti	  sani	  di	  
controllo	   è	   stata	   evidenziata	   una	   significativa	   riduzione	   volumetrica	   della	  
sostanza	  grigia	  dell’ippocampo	  sinistro	  e	  un	  trend	  verso	  la	  significatività	  statistica	  
per	   l’ippocampo	   destro	   (tali	   riduzioni	   volumetriche	   della	   grigia	   ippocampale	  
mantenevano	   bilateralmente	   tale	   trend	   verso	   la	   significatività	   statistica	   anche	  
dopo	  la	  normalizzazione).	  
	  
CONCLUSIONE:	   l’alterazione	   volumetrica	   della	   sostanza	   grigia	   ippocampale	  
evidenziata	   nel	   nostro	   studio	   potrebbe	   essere	   interpretata	   come	   un	   possibile	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FIRST	  PART:	  INTRODUCTION	  
	  
1.	  BEYOND	  THE	  KRAEPELINIAN	  DICHOTOMY	  
	  
Schizophrenic	   and	   affective	   disorders	   are	   complex	   and	   disabling	   psychiatric	  
diseases	  whose	  classical	  nosography	  and	  classification	  are	  still	  under	  challenging	  
debate	   aiming	   to	   overcome	   the	   traditional	   “Kraepelinian	   Dichotomy”	   between	  
Dementia	  Praecox	  and	  manisch-­‐depressive	  Irresein	  (Kraepelin	  E	  1899).	  	  
More	   than	   100	   years	   ago,	   Emil	   Kraepelin	   split	   the	   non-­‐organic	   (so-­‐called	  
functional)	   psychoses	   into	   two	   disorders	   and	   thereby	   created	   a	   dichotomous	  
approach	   to	   classification	   that	   persists	   to	   this	   day.	   For	   the	  past	   hundred	   years	  
most	   clinical	   work	   and	   research	   in	   psychiatry	   has	   proceeded	   under	   the	  
assumption	  that	  schizophrenia	  and	  bipolar	  affective	  disorder	  are	  distinct	  entities	  
with	  separate	  underlying	  disease	  processes	  and	  treatments.	  Although	  Kraepelin	  
himself	  came	  to	  question	  the	  validity	  of	  this	  dichotomy,	  it	  has	  become	  reified	  in	  
the	   American	   Psychiatric	   Association’s	   Diagnostic	   and	   Statistical	   Manual	   of	  
Mental	  Disorders	  (DSM),	  as	  well	  as	  WHO’s	  International	  Classification	  of	  Diseases	  
(ICD).	   In	   the	   absence	   of	   ‘laboratory’	   tests	   based	   on	   a	   solid	   understanding	   of	  
pathogenesis,	   the	   criteria	   available	   to	   psychiatry	   for	   validating	   nosological	  
categories	  have	  been	  restricted	  to	  clinical	   features,	  outcome	  and	  family	  history	  
(Robins	   and	   Guze	   1970).	   It	   is	   widely,	   but	   erroneously,	   assumed	   that	   the	   two	  
disorders	  are	  discrete,	  natural	  disease	  entities	  with	  distinct	  pathogenesis,	  which	  
can	  be	  identified	  by	  current	  operational	  diagnostic	  conventions.	  	  
This	  belief	  has	  survived	  despite	  the	  fact	  that,	  although	  typical	  schizophrenia	  and	  
bipolar	  disorder	  are	  often	  seen,	  many	  patients	  have	  both	  psychotic	  and	  affective	  
symptoms	  over	  the	  course	  of	  their	  illnesses	  and	  it	  is	  not	  uncommon	  for	  patients	  
to	   receive	   both	   diagnoses	   at	   different	   times	   (Owen	   and	   Craddock	   2009).	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Moreover,	  many	  individuals	  with	  severe	  psychiatric	  illness	  have	  both	  prominent	  
mood	  and	  psychotic	  symptoms,	  raising	  the	  possibility,	  indeed	  the	  likelihood,	  that	  
there	   is	   not	   a	   neat	   biological	   distinction	   between	   schizophrenia	   and	   bipolar	  
affective	  disorder	  (Craddock	  and	  Owen	  2005).	  	  
There	   is	   increasing	   evidence	   for	   phenomenological,	   biological	   and	   genetic	  
overlap	  between	  schizophrenia	  and	  bipolar	  disorders	   (Potash	  2006;	  Potash	  and	  
Bienvenu	  2009;	   Purcell	   et	   al.	   2009).	   Evidence	  has	   been	   gradually	   accumulating	  
over	   10-­‐20	   years	   from	   genetic	   epidemiology	   that	   is	   inconsistent	   with	   the	  
dichotomous	   view.	   Recent	   molecular	   genetic	   findings	   are	   most	   persuasive.	   In	  
The	  Lancet,	  Paul	  Lichtenstein	  and	  colleagues	  (Lichtenstein	  et	  al.	  2009)	  report	  the	  
largest	  family	  study	  of	  schizophrenia	  and	  bipolar	  disorder	  ever	  undertaken.	  They	  
studied	   more	   than	   2	   million	   nuclear	   families,	   which	   were	   identified	   from	   the	  
Swedish	   population	   and	   hospital-­‐discharge	   registers.	   Craddock	   and	   Owen	   say	  
that	  these	  results	  are	  clear:	  first-­‐degree	  relatives	  of	  probands	  with	  schizophrenia	  
or	  bipolar	  disorder	  have	  an	  increased	  risk	  of	  both	  disorders	  (Craddock	  and	  Owen	  
2010).	   Moreover,	   there	   is	   evidence	   from	   half-­‐siblings	   and	   adopted-­‐away	  
relatives	  that	  this	   is	  due	  substantially	  to	  genetic	  factors.	  Classical	   family	  studies	  
(Berrettini	  2000;	  Bramon	  and	  Sham	  2001),	  twin	  studies	  (Cardno	  et	  al.	  2002)	  and	  
recent	  molecular	  genetic	  studies	  (Purcell	  et	  al.	  2009;	  Owen	  et	  al	  2007;	  Craddock	  
et	   al	   2005)	   support	   the	   hypothesis	   of	   overlapping	   susceptibility	   between	   the	  
disorders	   (Craddock	   and	   Owen	   2007).	   Additionally,	   genome-­‐wide	   association	  
studies	   (GWAS)	   have	   demonstrated	   the	   existence	   of	   common	   DNA	   variants	  
(single	   nucleotide	   polymorphisms,	   SNPs)	   that	   influence	   risk	   of	   both	  
schizophrenia	  and	  bipolar	  disorder.	  There	  is	  direct	  molecular	  genetic	  support	  for	  
a	   substantial	   genetic	  overlap	  between	   schizophrenia	  and	  bipolar	  disorder	   from	  
the	   recent	   large-­‐scale	   GWAS	   of	   bipolar	   disorder	   and	   schizophrenia	   in	   which	  
thousands	   of	   individuals	   have	   been	   studied	   for	   hundreds	   of	   thousands	   of	  
common	   DNA	   variants	   spread	   across	   the	   genome	   (Badner	   and	   Gershon	   2002;	  
Vazza	  et	  al.	  2007;	  O’Donovan	  et	  al.	  2008;	  Moskvina	  et	  al.	  2009;	  Green	  et	  al.	  2010;	  
Purcell	  et	  al.	  2009).	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The	   studies	   described	   above	   indicate	   that	   schizophrenia	   and	   bipolar	   disorder	  
(and	  recurrent	  depression)	  do	  not	  “breed	  true”,	  but	  have	  an	  overlap	   in	  genetic	  
risk	  and	  are	  therefore	  likely	  to	  share	  some	  aspects	  of	  pathogenesis.	  
	  
	  
2.	  THE	  BIPOLAR-­‐SCHIZOPHRENIC	  “SPECTRUM”	  
	  
The	  DSM	  and	   ICD	   systems,	   so-­‐called	   “categorical”	  models,	   have	   proven	   useful,	  
facilitating,	  considerable	  gains	  in	  research,	  since	  the	  DSM	  initiated	  this	  system	  of	  
dichotomous	  (present/absent)	  decision	  making,	  thus	  improving	  comprehension,	  
communication	   and	   sharing	   of	   clinical	   information	   between	   clinicians	   from	  
different	  parts	  of	  the	  world	  (Jablensky	  1999).	  The	  “dichotomy”	  also	  formed	  the	  
basis	  of	   the	  operational	  diagnostic	   criteria	   that	  brought	  a	  degree	  of	   rigour	  and	  
reproducibility	  to	   psychiatric	   research	   (Craddock	   and	   Owen	   2005).	   Any	  
psychiatrist	   with	   experience	   of	   functional	   psychotic	   illness	   knows	   that	   many	  
patients	  do	  not	  have	  disorders	  that	  conform	  to	  either	  prototypical	  dichotomous	  
category.	  Many	  individuals	  receive	  one	  diagnosis	  at	  one	  time	  or	  from	  one	  team	  
and	  the	  alternative	  diagnosis	  at	  a	  different	  time	  or	  from	  another	  team.	  Further,	  
findings	  emerging	  from	  many	  fields	  of	  psychiatric	  research,	  such	  as	  neuroimaging,	  
neuropathology	   and	   neuropsychology,	   do	   not	   fit	   well	   with	   the	   traditional	  
dichotomous	  model	  (Murray	  et	  al.	  2004).	  	  
Nowadays,	  the	  categorical	  approach	  to	  psychiatric	  nosography	  is	  in	  contrast	  with	  
the	   recent	  neurobiological,	  neuropsychological	  and	  genetic	   findings	   in	  affective	  
and	  schizophrenic	  disorders.	  	  
Emil	   Kraepelin	   himself,	   in	   his	   latter	   years,	   was	   close	   to	   revising	   his	   own	  
celebrated	  dichotomy	  between	  manic-­‐depressive	  insanity	  and	  dementia	  praecox	  
in	   order	   to	   take	   account	   of	   a	   large	   group	   of	   intermediate	   psychoses.	   He	  
continued	   to	  develop	   and	   refine	  his	   ideas	   about	   psychiatric	   diagnoses,	   and	  his	  
thinking	  had	  in	  many	  ways	  moved	  on	  from	  the	  dichotomous	  classification	  by	  the	  
end	   of	   his	   life	   (Jablensky	   1999;	   Jablensky	   2010;	   Craddock	   and	   Owen	   2007).	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Kraepelin	   conceptualized	   the	   individual	   course	   of	   affective	   disorders	   over	   a	  
lifetime	  as	  a	  movement	  along	  the	  continuum	  from	  normal	  fluctuations	  in	  mood	  
(including	  basic	  states	  or	  temperaments)	  via	  full-­‐blown	  mania	  and	  depression	  to	  
psychotic	  syndromes:	  he	  described	  a	  continuum	  from	  syntonic,	  mood-­‐	  congruent	  
psychotic	   affective	   disorders	   to	   parathymic,	   mood-­‐incongruent	   psychotic	  
disorders	  (Angst	  and	  Gamma	  2008).	  
Although	   the	   dichotomous	   view	  has	  dominated	   clinical	   psychiatry	   for	   over	   100	  
years,	  there	  has	  been	  a	  long	  history	  of	  dissent.	  Many	  nosologists	  have	  developed	  
their	   own	  models	   and	   approaches:	   important	   recent	   examples	   include	   Crow’s	  
continuum	   model	   (Crow	   2008),	   the	   spectrum	   models	   of	   bipolarity	   of	   Angst	  
(Angst	  2007;	  Phelps	  et	  al.	  2008)	  and	  Akiskal	  (Akiskal	  and	  Pinto	  1999;	  Evans	  et	  al.	  
2005;	  Akiskal	  2007),	  and	  Marneros’	  focus	  on	  schizoaffective	  disorder	  (Marneros	  
2006).	  	  
When	   considering	   complex	   psychiatric	   infirmities,	   such	   as	   schizophrenia	   and	  
affective	  disorders,	  a	  categorical	  approach	  is	  limiting	  (Frank	  2011):	  it	  is	  important	  
to	   take	   a	   “longitudinal”	   approach	   to	   diagnosis	   and	   to	   consider	   the	   nature	   and	  
occurrence	   of	   psychotic	   and	   affective	   symptoms	   across	   the	   patient’s	   illness	  
history.	   It	   is	  also	  of	   fundamental	   importance	   to	  consider	  mixed	  o	   subthreshold	  
symptomatology	   (Cassano,	  Mantua,	  and	  Fagiolini	  2011).	   	  Besides,	   the	  reliability	  
and	  stability	  of	   the	  DSM-­‐IV	   schizoaffective	  diagnosis	   is	  poor	   (Forrester,	  Owens,	  
and	   Johnstone	   2001;	   Kane	   2010).	   The	   relative	   proportions	   of	   psychotic	   and	  
affective	   symptoms	   as	   well	   as	   the	   type	   (bipolar	   type,	   depressive	   type)	   of	   the	  
affective	  syndrome	  therefore	  are	  key	  components	  in	  its	  diagnosis	  and	  subtyping,	  
generating	   a	   de-­‐facto	   dimensional	   concept	   of	   schizoaffective	   disorder.	   The	  
nosographic	  heterogeneity	  of	  schizoaffective	  disorder	  reflects	  the	  possibility	  that	  
this	   disorder	   may	   straddle	   the	   middle	   of	   a	   continuum	   between	   schizophrenia	  
and	   bipolar	   disorder	   (Keshavan	   et	   al.	   2011).	   One	   of	   the	   criticisms	   of	  
schizoaffective	   disorder	   by	   clinical	   and	   research	   psychiatrists	   is	   the	   lack	   of	  
reliability	  and	  temporal	  stability	  that	  has	  been	  reported	  using	  current	  definitions	  
(Maj	  et	  al.	  2000).	  However,	  this	  is	  an	  almost	  inevitable	  consequence	  of	  the	  overly	  
restrictive	  nature	  of	  current	  definitions	  of	  schizoaffective	  disorder,	  together	  with	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the	   tendency	   of	   clinicians	   to	   make	   diagnoses	   “cross-­‐sectionally”	   rather	   than	  
“longitudinally”	  (Craddock	  and	  Owen	  2007).	  
Intermediate	  cases	  suggest	  that	  the	  symptoms	  and	  signs	  constituting	  bipolar	  and	  
schizophrenic	   disorders	   may	   be	   continuously,	   not	   dichotomously,	   distributed;	  
there	  may	  be	  no	  point	  of	   “real	   cleavage”	   (Phelps	   et	   al.	   2008).	   This	   recognition	  
has	   led	   some	   clinicians	   and	   researchers	   to	   call	   for	   a	   diagnostic	   model	   that,	  
moving	   to	   a	   “dimensional	   perspective”,	   formally	   recognizes	   a	   continuous	  
spectrum	  from	  schizophrenic	  to	  bipolar	  (and	  recurrent	  depressive)	  disorders.	  
	  
The	   concept	   of	   spectrum,	   when	   considering	   a	   particular	   psychopathological	  
phenomenon,	   is	   referred	   to	   a	   variety	   of	   syndromes	   that,	   despite	   an	   apparent	  
heterogeneity	   of	   symptoms	   and	   clinical	   manifestations,	   have	   in	   common	   the	  
same	   etiologic	   determinants	   or	   common	   pathogenetic	   mechanisms.	   In	   a	  
dimensional	  view,	  the	  concept	  of	  spectrum	  is	  applied	  to	  those	  types	  of	  different	  
disorders,	  which	  share	  the	  same	  kind	  of	  psychopathological	  phenomena	  though	  
in	  a	  continuum	  or	  gradation	  of	  severity.	  	  
As	   pointed	   out	   by	   Jules	   Angst	   (Angst	   2007),	   for	   the	   first	   time	   in	   psychiatric	  
history	   Kretschmer	   in	   1921	   proposed	   a	   dimensional	   concept	   (from	   normal	   to	  
pathological)	  for	  schizophrenia	  (schizothymic	  –	  schizoid	  –	  schizophrenic)	  and	  for	  
affective	  disorders	  (cyclothymic	  temperament	  –	  cycloid	  “psychopathy”	  –	  manic-­‐
depressive	  disorder),	  a	  few	  years	  later	  carried	  on	  by	  Bleuler	  	  in	  1922.	  	  
The	  term	  “spectrum”	  was	   first	  used	   in	  psychiatry	   in	  1968	  for	   the	  schizophrenia	  
spectrum,	   which	   integrated	   schizoid	   personalities	   (Kety	   et	   al.	   1968).	   In	   more	  
recent	   years,	   the	   hypothesis	   of	   a	   continuum	   or	   spectrum	   of	   schizophrenia-­‐
related	   phenotypes	   is	   supported	   by	   frequent	   observation	   that	   apparently	  
different	   psychotic	   disorders	   tend	   to	   aggregate	   in	   first	   degrees	   relatives	   of	  
schizophrenia-­‐diagnosed	   patients	   (Siever	   and	   Davis	   2004).	   Epidemiological	  
studies	  suggest	  that	  genetic	  susceptibility	  to	  schizophrenia	  is	  shared	  with	  genetic	  
predisposition	  to	  other	  related	  syndromes	  (for	  example,	  schizotypal	  or	  paranoid	  
personality	  disorder)	  (Baron	  and	  Risch	  1987;	  Kety	  et	  al.	  1994).	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With	   regard	   to	   mood	   or	   affective	   disorders,	   in	   1977	   Akiskal	   proposed	   a	  
cyclothymic-­‐bipolar	  spectrum	  and	  in	  1981	  Klerman	  suggested	  a	  mania	  spectrum	  
(Akiskal	  et	  al.	  1977;	  Klerman	  1981).	  According	  to	  Phelps	  and	  colleagues	  (Phelps	  
et	   al.	   2008)	   Kraepelin	   emphasized	   not	   mania	   but	   rather	   a	   high	   degree	   of	  
recurrence	   as	   the	   principal	   identifying	   feature	   of	  manic-­‐depressive	   course	   and	  
Klerman	  included	  in	  his	  spectrum	  a	  bipolar	  category	  (could	  be	  considered	  bipolar	  
V	  type)	  in	  which	  individuals	  had	  only	  depression,	  no	  hypomania	  or	  mania,	  but	  a	  
high	  familial	  incidence	  of	  bipolar	  disorder.	  Later,	  the	  concept	  of	  bipolar	  spectrum	  
was	  expanded	  in	  order	  to	  encompass	  all	  kind	  of	  disturbances	  that	  demonstrate	  a	  
mood	  alteration	  as	   the	  principal	  psychopatological	  element,	   from	  subthreshold	  
to	  full	  psychotic	  manic	  disorders,	  in	  a	  continuum	  of	  symptom	  severity:	  affective	  
personalities	   -­‐	   dysthymia/cyclothymia	   -­‐	   recurrent	   major	   depressive	   disorder	   -­‐	  
bipolar	  disorder	  II	  and	  I	  (Akiskal	  1983;	  Akiskal	  and	  Pinto	  1999;	  Akiskal	  2007).	  
JR	  Kelsoe	  (Kelsoe	  2003)	  argued	  that	  the	  existing	  data	  coming	  from	  various	  fields	  
of	  research	  in	  bipolar	  and	  schizophrenic	  disorders	  may	  best	  fit	  a	  model	  in	  which	  
different	   set	   of	   genes	   predispose	   to	   overlapping	   phenotypes	   in	   a	   continuum.	  
Schizophrenia	   and	   affective	   disorders	   do	   not	   follow	   a	   Mendelian	   form	   of	  
transmission,	  rather	  they	  demonstrate	  a	  complex	  pattern	  of	  genetic	  transmission	  
(Kendler	   2006).	   According	   to	   Kelsoe,	   the	   problem	   with	   the	   bipolar	   spectrum	  
described	  above	  is	  that	  it	  does	  not	  include	  a	  number	  of	  diagnostic	  and	  syndromic	  
entities	   that	   also	   occur	   in	   the	   families	   and	   co-­‐twins	   of	   bipolar	   patients.	  
Specifically,	   this	   should	   include	   unipolar	   depression,	   dysthymia,	   as	   well	   as,	  
psychotic	   mood	   disorder,	   schizoaffective	   disorder	   and	   possibly	   schizophrenia	  
(Kelsoe	  1999;	  Kelsoe	  2003).	  Given	  the	  apparent	  overlap	  of	  regions	  of	  the	  genome	  
implicated	   in	   bipolar	   disorder	   with	   those	   for	   schizophrenia	   (Kelsoe	   1999;	  
Berrettini	  2000),	  these	  data	  suggest	  the	  possibility	  that	  the	  same	  gene	  in	  each	  of	  
these	   regions	  predisposes	   to	  both	  bipolar	  disorder	   and	   schizophrenia.	   This	  will	  
not	  be	  conclusively	  known	  until	  the	  genes	  are	  definitively	  identified.	  It	  is	  possible	  
that	   each	   region	   contains	   separate	   genes	   for	   each	   disorder	   that	   are	  
coincidentally	  near	  each	  other.	  However,	  if	  a	  substantial	  portion	  of	  the	  genes	  for	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these	  two	  disorders	  is	  common,	  it	  will	  raise	  the	  challenging	  question	  of	  how	  the	  
same	  genes	  can	  lead	  to	  two	  different	  phenotypes.	  	  
Kelsoe	  proposed	  a	  “multiple	  threshold	  model”	  (Fig.	  1)	  to	  combine	  a	  quantitative	  
trait	  model	  of	   transmission	   (polygenic	   transmission)	  with	  qualitatively	  different	  
phenotypes,	  lying	  on	  the	  spectrum:	  the	  more	  polygenic	  susceptibility	  alleles	  one	  
person	  has,	  the	  higher	  is	  the	  value	  of	  the	  quantitative	  trait;	  qualitatively	  different	  
traits	  result	  when	  a	  critical	  threshold	  is	  exceeded	  and	  different	  thresholds	  lead	  to	  
different	   disorders	   (unipolar	   depression	   -­‐	   bipolar	   disorder	   -­‐	   schizoaffective	  
disorder	  -­‐	  schizophrenia).	  	  
	  
Figure	  1.	  Multiple	  Threshold	  model	  (from	  Kelsoe	  2003).	  
	  
	  
Figure	  2.	  Gene	  x	  Environment	  interactions	  (from	  Kelsoe	  2003).	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In	  addition,	  allelic	  heterogeneity,	  the	  presence	  of	  different	  mutations	  within	  the	  
same	   susceptibility	   gene,	   epistatic	   gene-­‐gene	   interaction	   and	   different	   gene-­‐
environment	   interactions	   (Fig.	   2)	   may	   produce	   the	   variety	   of	   phenotypes	  
observed	  (Kelsoe	  2003).	  
	  
In	  conclusion,	  as	  highlighted	  by	  Nicholas	  Craddock	  and	  Michael	  Owen,	  the	  recent	  
findings	   are	   compatible	   with	   a	   model	   of	   functional	   psychosis	   in	   which	  
susceptibility	   to	   a	   spectrum	   of	   clinical	   phenotypes	   is	   under	   the	   influence	   of	  
overlapping	  sets	  of	  genes	  which,	  together	  with	  environmental	  factors,	  determine	  
an	  individual’s	  expression	  of	  illness	  (Fig.	  3).	  
	  
	  
Figure	   3.	   Possible	   relationship	   between	   susceptibility	   genes,	   environment	   and	   clinical	  
phenotypes	  (from	  Craddock	  and	  Owen,	  2005).	  
	  
In	  addition	  to	  the	  interface	  between	  bipolar	  disorder	  and	  schizophrenia,	  there	  is	  
genetic	  overlap	  between	  the	  functional	  psychoses	  and	  major	  depressive	  disorder	  
with	  extension	  into	  subclinical	  (or	  normal)	  variation.	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According	   to	   Craddock	   &	   Owen	   (2005),	   most	   patients	   want	   to	   be	   given	   an	  
unambiguous	   and	   accurate	   diagnosis,	   but	   psychiatrists	   are	   understandably	  
reluctant	  to	  be	  too	  dogmatic	  in	  the	  early	  stages	  of	  psychotic	  illness,	  recognizing	  
that	   the	   cross-­‐sectional	   picture	   may	   change	   longitudinally,	   often	   frustrating	  
patients,	   leading	   to	   diagnostic	   revisions	   between	   categories	   and	   creating	   an	  
impression	  that	  psychiatrists	  are	  indecisive	  or	  incompetent.	  	  	  
Moving	   to	   a	   spectrum	   concept	   with	   recognition	   of	   overlapping	   pathogenetic	  
factors	   and	   varying	   expression	   (dependent	   upon	   both	   genetic	   risk	   and	  
environmental	   exposure)	   would	   allow	   a	   confident	   and	   clear	   diagnosis	   to	   be	  
offered	  (perhaps	  ‘psychosis-­‐spectrum	  illness’	  or	  ‘mood–	  reality	  disorder’),	  with	  a	  
clear	  explanation	  that	  some	  specific	  tests	  and	  a	  period	  of	  observation	  will	  help	  to	  
clarify	  the	  likely	  course	  of	  illness	  and	  response	  to	  treatment.	  
Data	  from	  the	  ongoing	  large	  scale	  molecular	  genetic	  studies	  (particularly,	  but	  not	  
exclusively,	  whole	   genome	   association	   studies),	   together	  with	   data	   from	  other	  
areas	   of	   neuroscience,	   offer	   the	   opportunity	   of	   starting	   to	   put	   psychiatric	  
classification	   on	   a	   robust	   framework	   that	   has	   biological	   validity	   (Craddock	   and	  
Owen	  2007).	  
It	   seems	   likely	   that	   sets	   of	   overlapping	   genes	   that	   confer	   risks	   along	   different	  
domains	  of	   psychopathology,	  will	   be	   gradually	   identified,	   corresponding	   to	   the	  
disruption	   of	   different	  brain	   systems.	   Unravelling	   the	   neurobiology	   underlying	  
these	   overlaps	   will	   shed	   light	   on	   the	   bewildering	   degree	   of	   “comorbidity”	  
observed	  across	  disorders	  and	  the	  widespread	  non-­‐specificity	  of	  treatments.	  
Finally,	   we	   now	   have	   at	   our	   disposal	   powerful	   molecular	   genetic	   tools	   that	  
should	   allow	   us	   to	   identify	   the	   biological	   systems	   that	   are	   involved	   in	   disease	  
pathogenesis.	   These	   techniques	   allow	   us	   to	   study	   biological	   systems	   in	   large	  
numbers	  of	  individuals	  whilst	  they	  are	  alive.	  For	  the	  first	  time	  in	  psychiatry,	  this	  
provides	   the	   opportunity	   to	   validate	   our	   diagnostic	   concepts	   and	   procedures	  
against	   biologically	   relevant	   criteria	   that	   in	   many	   cases	   will	   relate	   to	   the	  
effectiveness	  of	  treatments	  (Craddock	  and	  Owen	  2007).	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3.	  STRUCTURAL	  MRI	  IN	  THE	  SPECTRUM	  
	  
The	   impressive	  developments	   in	  neuroimaging	  are	   likely	  to	  provide	  us	  with	  the	  
power	   to	   study	   the	   functioning	   of	   specific,	   relevant	   brain	   systems	   in	   vivo	   in	  
individuals	   during	   differing	   phases	   of	   illness	   and	   in	   response	   to	   varying	  
environmental	   situations.	   Craddock	   and	   Owen	   (2007)	   imagine	   that	   these	  
approaches	  will	   be	   complemented	   by	   developments	   in	  many	   other	   fields,	   and	  
this	  will	  facilitate	  the	  bringing	  together	  of	  diverse	  domains	  of	  research	  evidence	  
that	  can	  be	  synthesized	  into	  models	  of	  brain	  function	  and	  dysfunction	  and	  their	  
relationship	  with	  psychopathology.	  
Neuroimaging	  has	  been	  embraced	  by	  investigators	  applying	  diverse	  methods	  to	  
examine	   brain	   structure	   and	   function	   in	   psychiatric	   disorders.	   In	   vivo	  
measurement	   is	   afforded	   by	   magnetic	   resonance	   imaging	   (MRI)	   examining	  
neuroanatomy	   through	   structural	   MRI	   (sMRI),	   connectivity	   through	   diffusion	  
tensor	   imaging	   (DTI),	   and	   neurochemistry	   through	   magnetic	   resonance	  
spectroscopy	   (MRS).	   Magnetic	   resonance	   also	   enables	   examination	   of	   brain	  
physiology	   using	   functional	   MRI	   (fMRI)	   methods	   (Gur,	   Keshavan,	   and	   Lawrie	  
2007).	   In	  the	  absence	  of	  quantitative	  analysis,	  routine	  brain	   imaging	  cannot	  aid	  
in	   the	   differential	   diagnosis	   of	   psychiatric	   diseases	   without	   considering	   the	  
clinical	   presentation.	   Thus	   far,	   studies	   using	   imaging	   techniques	   to	   determine	  
prognosis	   or	   treatment	   response	   have	   not	   generated	   sufficiently	   replicated	  
findings.	  There	  are,	  however,	  encouraging	  results	  from	  several	  studies	  evaluating	  
these	  technologies	  as	  possible	  predictors	  of	  diagnosis	  (Agarwal	  et	  al.	  2010).	  
In	  addition,	  heterogeneous	  structural	  MRI	  findings	  can	  be	  influenced	  by	  various	  
factors	  including	  scan	  acquisition	  parameters,	  image	  quality,	  hardware/software	  
employed	  in	  the	  tracing	  procedure	  and	  type	  of	  segmentation	  technique	  (manual	  
or	  automatic)	  (Geuze,	  Vermetten,	  and	  Bremner	  2005).	  	  
Currently,	   the	   “gold	   standard”	   for	   determining	   the	   volumes	   of	   specific	   brain	  
areas	  (Region	  of	  Interest,	  ROI)	   is	  the	  “manual	  tracing”	  method	  (Tae	  et	  al.	  2008;	  
Doring	  et	  al.	  2011):	  however,	  this	  technique	  has	  the	  disadvantage	  of	  being	  time-­‐
consuming	  and	  operator-­‐dependent.	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Semi-­‐automated	   and	   automated	   segmentation	   techniques	   have	   generated	  
intense	  interest	  given	  the	  wide	  range	  of	  clinical	  applications	  for	  MRI	  volumetry	  in	  
the	   last	   decades.	   In	   recent	   years,	   the	   ROI	   analytic	   manual	   approach	  
initially	  applied	  has	  been	  replaced	  by	  semi	  automated	  methods,	  such	  as	  design-­‐
based	   Stereology	   (Keshavan	   et	   al.	   1995;	   Sheline	   et	   al.	   1996;	   Schmitz	   and	   Hof	  
2005)	   or	   by	   automated	   methods	   for	   regional	   parcellation	   and	   voxel-­‐based	  
morphometry	   (VBM)	   (Ashburner	   and	   Friston	   2000),	   that	   can	   efficiently	   yield	  
information	  on	   the	   entire	   brain,	   permitting	   validation	  of	   reported	   findings	   and	  
new	  discovery	  of	  other	  affected	  regions.	  
	  
A	  lot	  of	  interest	  is	  focusing	  on	  brain	  structural	  abnormalities	  in	  patients	  suffering	  
from	  schizophrenia	  and	  bipolar	  disorder.	  	  
A	  huge	  amount	  of	  neuroimaging	  studies	  has	  been	  published	  so	  far,	  however	  the	  
literature	   is	   heterogeneous	   and	   there	   is	   still	   some	   degree	   of	   uncertainty	  
concerning	  what	  key	  regions	  are	  involved	  in	  the	  pathogenesis	  of	  such	  disorders.	  
Schizophrenia	  and	  Bipolar	  disorder	  have	  a	  number	  of	  overlapping	  symptoms	  and	  
risk	   factors,	   but	   it	   is	   not	   yet	   clear	   if	   the	   disorders	   are	   characterized	   by	   similar	  
deviations	   in	   brain	   morphometry	   or	   whether	   any	   such	   deviations	   reflect	   the	  
impact	  of	  shared	  susceptibility	  genes	  on	  brain	  structure.	  	  
One	  of	  the	  best-­‐characterized	  brain	  abnormalities	  in	  Schizophrenia	  is	  gray	  matter	  
reduction,	   consistently	   reported	   by	   numerous	  morphometric	   studies	   using	   ROI	  
or	  VBM	  analyses.	  In	  this	  disorder,	  brain	  volumes	  have	  consistently	  been	  found	  to	  
be	   decreased,	   particularly	   in	   the	   frontal	   and	   temporal	   lobes,	   including	   the	  
anterior	  cingulate	  (Baiano	  et	  al.	  2007),	  superior	  temporal	  gyrus	  (Sun	  et	  al.	  2009),	  
hippocampus	   (Steen	   et	   al.	   2006),	   thalamus	   (Konick	   and	   Friedman	   2001),	   and	  
striatum,	  with	  increases	  in	  the	  lateral	  and	  third	  ventricles	  (Vita	  et	  al.	  2006).	  	  
These	  findings	  are	  variously	  replicated	  and	  reported	  in	  reviews	  or	  meta-­‐analyses	  
including	  patients	  with	  first-­‐episode	  or	  chronic	  schizophrenia	  (Wright	  et	  al.	  2000;	  
Shenton	  et	  al.	  2001;	  Honea	  et	  al.	  2005;	  Pantelis	  et	  al.	  2005;	  Olabi	  et	  al.	  2011)	  and	  
also	  in	  studies	  with	  individuals	  at	  high	  risk	  for	  schizophrenia	  (Chan	  et	  al.	  2011).	  
	  12	  
On	   the	   other	   hand,	   the	  majority	   of	   structural	   neuroimaging	   studies	   in	   Bipolar	  
Disorder	  are	  ROI-­‐based	  and	  the	  literature	  consists	  of	  a	  small	  number	  of	  studies	  
examining	   a	   limited	   number	   of	   structures,	   for	   example	   amygdala	   (Strakowski,	  
Adler,	  and	  DelBello	  2002)	  or	  anterior	  cingulate	  (Konarski	  et	  al.	  2008),	  with	  small	  
sample	  sizes	  and	  contradicting	  evidences	  (McDonald	  et	  al.	  2004;	  Kempton	  et	  al.	  
2008).	   Although	   VBM	   studies	   in	   bipolar	   disorder	   are	   increasing	   in	   number	   in	  
recent	  years,	   findings	  remain	  contradictory;	  however	  two	  recent	  meta-­‐analyses	  
revealed	  gray	  matter	  reduction	  in	  the	  insula	  and	  anterior	  cingulate	  cortex	  (Bora	  
et	  al.	  2010;	  Ellison-­‐Wright	  and	  Bullmore	  2010).	  Ventricular	  enlargement	  and	  the	  
presence	   of	   white	   matter	   hyper-­‐intensities	   are	   among	   the	   most	   consistently	  
reported	  abnormalities	  (Kempton	  et	  al.	  2008;	  Strakowski	  et	  al.	  2002).	  	  
With	   regard	   to	   hippocampal	   volumes,	   data	   emerging	   from	   ROI-­‐based	   or	   VBM	  
studies	  are	  extremely	  variable:	   the	  majority	  of	   them	  failed	  to	  detect	  significant	  
volume	  differences	  between	  bipolar	  patients	  and	  healthy	  controls	  (Hauser	  et	  al.	  
2000;	  Altshuler	  et	  al.	  2000;	  Brambilla	  et	  al.	  2003;	  Strasser	  et	  al.	  2005;	  Adler	  et	  al.	  
2007);	   however	   a	   few	   studies	   report	   significant	   hippocampal	   reductions	   in	  
patients	  compared	  to	  control	  subjects	  (Blumberg	  et	  al.	  2003).	  	  
Recently,	   Chepenik	   and	   colleagues	   reported	   hippocampal	   decrease	   in	   two	  
different	  studies	  comparing	  bipolar	  patients	  vs.	  healthy	  controls.	  They	  found	  that	  
hippocampal	  volumes	  were	  significantly	   smaller	   in	  bipolar	  compared	   to	  control	  
subjects	  and,	   analyzing	   the	  BDNF	  val66met	  polymorphism,	   the	  presence	  of	   the	  
BDNF	   met	   allele	   was	   associated	   with	   smaller	   hippocampal	   volumes	   in	   both	  
diagnostic	   groups:	   moreover	   the	   bipolar	   subgroup	   who	   carried	   the	   BDNF	  met	  
allele	  had	  the	  smallest	  hippocampi	  (Chepenik	  et	  al.	  2009);	  furthermore,	  bilateral	  
hippocampal	   reduction	   in	   bipolar	   patients	   correlated	   with	   verbal	   memory	  
impairment	  (Chepenik	  et	  al.	  2012).	  
According	   to	   Bearden	   and	   colleagues	   (Bearden	   et	   al.	   2008),	   localized	  
hippocampal	  decreases	  in	  patients	  with	  bipolar	  disorder	  are	  subtle	  end	  not	  easily	  
detectable	   with	   conventional	   volumetric	   measures.	   In	   a	   different	   study	   they	  
found	   out	   decreased	   volume	   in	   the	   CA1	   region	   of	   right	   hippocampus	   in	  
unmedicated	  bipolar	  patients,	  thus	  demonstrating	  the	  sensitivity	  of	  3D	  anatomic	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mapping	  methods	   for	   detecting	   subtle	   alterations	   in	   hippocampal	   structure	   in	  
bipolar	  disorder	  (Bearden	  et	  al.	  2008).	  
There	   are	   few	   morphometric	   studies	   comparing	   psychotic	   bipolar	   patients	   to	  
healthy	   controls,	   and	   these	   are	   mainly	   ROI-­‐based.	   Majority	   of	   these	   studies	  
report	   no	   volumetric	   abnormalities	   in	   the	   examined	   regions	   including	   the	  
amygdalo-­‐hippocampal	   complex,	   thalamus,	   superior	   temporal	   gyrus	   and	   insula	  
(Bora	   et	   al.	   2008).	   Volume	   reductions	   were	   occasionally	   reported	   only	   in	   the	  
subgenual	  cingulate	  cortex	  (Hirayasu	  et	  al.	  1999),	  left	  hippocampus	  (Velakoulis	  et	  
al.	  1999),	  while	  one	  study	  reported	  increased	  striatal	  volume	  (Getz	  et	  al.	  2002).	  
	  
Two	   meta-­‐analyses	   have	   sought	   to	   clarify	   the	   neuroanatomical	   differences	  
between	  bipolar	  and	  schizophrenia	  patients	  and	  to	  identify	  differences	  between	  
each	  patient	  group	  and	  healthy	  controls.	  	  
A	  meta-­‐analysis	  of	  VBM	  studies,	   that	  encompassed	   thousands	  of	   schizophrenia	  
and	  hundreds	  of	  bipolar	  patients,	   identified	  widespread	  gray	  matter	  reductions	  
in	   the	   schizophrenia	   group	   compared	   with	   healthy	   controls	   that	   included	   the	  
insula	   bilaterally,	   dorsolateral	   prefrontal	   cortex,	   superior	   temporal	   cortex,	  
bilateral	   hippocampal-­‐amygdala	   region,	   thalamus,	   anterior	   cingulate,	   medial	  
frontal	  gyrus	  and	  posterior	  cingulate;	  smaller	  gray	  matter	  volumes	  were	  found	  in	  
the	   right	   and	   left	   insula,	   perigenual	   anterior	   cingulate,	   and	   subgenual	   anterior	  
cingulate	   in	   the	   bipolar	   studies,	   though	   not	   in	   the	   bilateral	   hippocampal-­‐
amygdala	   regions.	   The	   areas	   of	   reduced	   gray	   matter	   observed	   in	   studies	   of	  
bipolar	   patients	   overlapped	   substantially	  with	   areas	   of	   reduced	   gray	  matter	   in	  
schizophrenia	   patients,	   though	   the	   reductions	   seen	   bilaterally	   in	   the	  
hippocampal-­‐amygdala	  area	  among	  schizophrenia	  patients	  were	  not	  observed	  in	  
bipolar	   patients.	   An	   area	   of	   the	   perigenual	   anterior	   cingulate	   cortex	   was	  
selectively	  smaller	  among	  bipolar	  patients	  than	  healthy	  controls,	  a	  region	  where	  
no	  differences	  between	  schizophrenia	  patients	  and	  healthy	  controls	  have	  been	  
found	   (Ellison-­‐Wright	  and	  Bullmore	  2010).	  Arnone	  and	  colleagues	  carried	  out	  a	  
meta-­‐analysis	   of	   volumetric	   studies,	   using	   a	   variety	   of	   methods	   to	   segment	  
magnetic	   resonance	   images,	   and	   found	   smaller	   volumes	   in	   the	   right	   amygdala	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among	   schizophrenia	   patients	  when	   they	  were	   directly	   compared	  with	   bipolar	  
patients	  (Arnone	  et	  al.	  2009).	  
In	  literature,	  there	  are	  relatively	  few	  studies	  directly	  comparing	  brain	  volumes	  in	  
patients	  with	   schizophrenia	   vs.	   bipolar	   disorder:	   one	   of	   the	   aims	   of	   the	   direct	  
comparison	   between	   patients	   group	   is	   to	   provide	   critical	   tests	   of	   hypotheses	  
derived	  form	  meta-­‐analysis	  in	  a	  controlled	  study.	  	  
Brown	   and	   colleagues	   (Brown	   et	   al.	   2011)	   performed	   a	   cross-­‐sectional	   VBM	  
study	  comparing	  17	  chronic	  schizophrenia	  and	  15	  chronic	  bipolar	  I	  patients	  and	  
21	  healthy	  subjects	  matched	  for	  age,	  gender	  and	  duration	  of	  illness.	  Whole	  brain	  
gray	  matter	   volume	   of	   both	   the	   schizophrenia	   and	   bipolar	   groups	  was	   smaller	  
than	  among	  healthy	  control	   subjects.	  Regional	   voxel-­‐wise	  comparisons	   showed	  
that	   gray	   matter	   volume	   was	   smallest	   within	   frontal	   and	   temporal	   regions	   of	  
both	   patient	   groups;	   a	   second	   ROI	   analyses	   found	   moderately	   large	   to	   large	  
differences	   between	   schizophrenia	   and	   healthy	   subjects	   in	   the	   amygdala	   and	  
hippocampus,	   but	   hippocampal	   volume	   in	   the	   bipolar	   group	   did	   not	   differ	  
significantly	   from	   the	   healthy	   control	   volume.	   Unlike	   Ellison-­‐Wright	   and	  
Bullmore’s	   study,	   there	   were	   no	   group	   differences	   in	   the	   perigenual	   anterior	  
cingulate.	  When	  schizophrenia	  and	  bipolar	  groups	  were	  directly	  compared,	   the	  
schizophrenia	   group	   showed	   smaller	   gray	   matter	   volumes	   in	   right	   subcortical	  
regions	  involving	  the	  right	  hippocampus,	  putamen,	  and	  amygdala.	  
A	  Croatian	  study	  aiming	  to	  compare	  hippocampal	  volumes	  in	  separate	  groups	  of	  
patients	   with	   schizophrenia,	   schizoaffective	   and	   bipolar	   disorder,	   reported	   no	  
significant	  difference	   in	  volume	  between	  bipolar	  patients	  and	  healthy	  controls,	  
whereas	  hippocampal	  volume	  was	  statistically	  significantly	  reduced	  in	  the	  group	  
of	  patients	  with	  schizophrenia	  and	  schizoaffective	  disorder,	  compared	  to	  either	  
bipolar	  disorder	  or	  control	  group	  (Radonić	  et	  al.	  2011).	  
In	   a	   recent	   3	   Tesla	   VBM	   study,	   comparing	   schizophrenic	   and	   psychotic	   bipolar	  
individuals,	   Yüksel	   and	   colleagues	   reported	   that	   schizophrenic	   patients	  
demonstrate	   gray	   matter	   reductions	   in	   multiple	   frontal	   and	   temporal	   regions	  
compared	  to	  healthy	  controls	  and	  in	  the	  subgenual	  cortex	  compared	  to	  psychotic	  
bipolar	   patients;	   gray	   matter	   volume	   was	   increased	   in	   the	   right	   posterior	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cerebellum	  in	  schizophrenia	  patients	  compared	  to	  controls;	  however,	  psychotic	  
bipolar	   patients	   did	   not	   show	   significant	   gray	   matter	   deficits	   compared	   to	  
healthy	   controls	   or	   schizophrenic	   patients.	   They	   claim	   that	   it	   is	   currently	   not	  
clear	  whether	  the	  negative	  findings	  in	  the	  bipolar	  disorder	  literature	  are	  a	  result	  
of	   sample	   selection,	   medication	   biases,	   technical	   issues	   or	   represent	   a	   true	  
biological	  pattern	  (Yüksel	  et	  al.	  2012).	  
Considering	  what	  has	  been	  described	  above,	  to	  date	  there	  is	  no	  consensus	  about	  
whether,	   and	   to	  what	   extent,	   gray	  matter	   loss	   in	   Schizophrenia	   is	  mirrored	   in	  
Bipolar	   Disorder	   and	   what	   is	   the	   effect	   of	   medication	   or	   other	   confounding	  
factors.	  Studies	  in	  family	  members	  of	  patients,	  who	  share	  the	  risk	  of	  the	  disease	  
but	   not	   the	   confounding	   factors,	  may	   help	   elucidate	  whether	   abnormalities	   in	  
brain	  structures	  are	  shared	  by	  both	  illnesses.	  
In	  family	  members	  of	  patients	  with	  schizophrenia	  have	  been	  found	  reductions	  in	  
whole	  brain	  and	  hippocampus	  volume,	  as	  reported	  in	  a	  meta-­‐analysis	  (Boos	  et	  al.	  
2007).	   Decreases	   in	   gray	   and	   white	   matter	   and	   increases	   in	   caudate	   nucleus	  
volumes	  have	  been	  reported	  in	  relatives	  of	  patients	  with	  bipolar	  disorder	  (Noga,	  
Vladar,	  and	  Torrey	  2001;	  van	  der	  Schot	  et	  al.	  2010).	  
Again,	  a	  few	  studies	  have	  directly	  compared	  patients	  with	  schizophrenia,	  bipolar	  
disorder	   and	   their	   first-­‐	   and	   second-­‐degree	   relatives.	   Increased	   familial	   risk	   of	  
schizophrenia	   and	   bipolar	   disorder	   was	   reported	   for	   white	   matter	   volume	  
reductions	  in	  the	  left	  frontal	  and	  temporoparietal	  regions	  (McDonald	  et	  al.	  2004).	  
Increased	  familial	  risk	  of	  schizophrenia	  but	  not	  of	  bipolar	  disorder	  was	  associated	  
with	  lateral	  end	  third	  ventricle	  enlargement	  (McDonald	  et	  al.	  2006),	  loss	  of	  gray	  
and	   white	   matter	   in	   the	   dorsolateral	   and	   ventrolateral	   prefrontal	   cortices	  
(McIntosh	   et	   al.	   2006)	   and	   thalamus	   (McIntosh	   et	   al.	   2004).	   Increased	   familial	  
risk	  of	  bipolar	  disorder	  but	  not	  of	  schizophrenia	  was	  associated	  with	  gray	  matter	  
loss	   in	   the	   right	   anterior	   cingulate	   gyrus	   and	   ventral	   striatum	   (McDonald	  et	   al.	  
2004).	   Finally,	   an	   abnormal	   shape	   of	   the	   hippocampus	   was	   reported	   in	  
schizophrenic	   patients	   but	   not	   in	   their	   family	   members,	   neither	   in	   bipolar	  
patients	  nor	  in	  their	  unaffected	  relatives	  (Connor	  et	  al.	  2004).	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In	  a	  recent	  paper,	  Hulshoff	  Pol	  and	  colleagues	  set	  out	  to	  study	  twins	  concordant	  
and	  discordant	   for	  Schizophrenia	  and	  Bipolar	  Disorder	   to	  examine	  whether	   the	  
genetic	  risk	  of	  these	  disorders	  is	  reflected	  in	  brain	  volumes	  and	  cortical	  thickness.	  
A	   total	   of	   310	   individuals	   from	   158	   twin	   pairs	   (discordant	   for	   schizophrenia,	  
concordant	   and	   discordant	   for	   bipolar	   disorder	   and	   healthy	   twin	   pairs)	   were	  
included.	  They	  found	  that	  overlapping	  genetic	  liabilities	  for	  the	  two	  disorders	  are	  
reflected	   in	  shared	  abnormalities	   in	  cortical	  gray	  and	  white	  matter.	  Specifically,	  
the	   elevated	   genetic	   risk	   of	   schizophrenia	   and	   bipolar	   disorder	   is	   most	  
prominently	   reflected	   in	   a	   global	   decrease	   in	  white	  matter	   volume,	   in	   specific	  
thinning	   of	   parahippocampal	   and	   orbitofrontal	   cortices	   and	   thickening	   of	  
temporoparietal	   and	   superior	   motor	   cortices;	   furthermore,	   increased	   genetic	  
liability	   for	   schizophrenia	   but	   not	   for	   bipolar	   disorder	   was	   associated	   with	   a	  
thicker	   right	   parietal	   cortex,	   whereas	   increased	   genetic	   liability	   for	   bipolar	  
disorder	   but	   not	   for	   schizophrenia	   was	   associated	   with	   enlarged	   intracranial	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SECOND	  PART:	  EXPERIMENTAL	  DATA	  
	  
1.	  AIM	  OF	  THE	  STUDY	  
	  
This	   study	   is	   part	   of	   a	  wider	   research	   funded	   by	   Regione	   Veneto	   and	   entitled	  
“Neural	   and	   cognitive	   endophenotypes	   in	   complex	   early-­‐onset	   psychiatric	  
diseases:	  a	  research	  on	  “common	  genes”	  in	  mood	  disorders	  and	  schizophrenia”.	  
	  
The	  aim	  of	  the	  present	  study	  was	  to	  investigate	  hippocampal	  gray	  matter	  volume	  
differences	   between	   a	   group	   of	   patients	   with	   bipolar-­‐schizophrenic	   spectrum	  
disorders	  and	  a	  group	  of	  healthy	  control	  subjects,	  by	  using	  volumetric	  magnetic	  
resonance	   imaging.	   In	   order	   to	   verify	   or	   exclude	   specific	   diagnosis-­‐related	  
volumetric	   differences,	   we	   performed	   cross-­‐sectional	   comparisons	   between	  
bipolar	  patients,	  schizophrenic	  patients	  and	  healthy	  controls.	  
Moreover,	  we	   identified	   a	   little	   sample	   of	   unaffected	   first-­‐degrees	   relatives	   of	  
the	  recruited	  patients	  and	  compared	  their	  hippocampal	  volumes	  with	  the	  same	  
control	   group,	   aiming	   to	   detect	   (or	   speculate)	   a	   putative	   structural	   marker	   in	  









2.1.	  SUBJECTS	  ENROLLMENT	  
The	  global	  research	  aimed	  to	  recruit	  patients	  suffering	  from	  different	  early-­‐onset	  
disorders	   throughout	   the	   bipolar-­‐schizophrenic	   spectrum,	   comprising	   bipolar	  
type	   I	   and	   II	   disorder	   (BD),	   recurrent	   major	   depressive	   disorder	   (MDD),	  
schizoaffective	  disorder	   (SA)	  and	  schizophrenia	   (SZ).	  Furthermore,	  we	  aimed	  to	  
enroll	  a	  sample	  of	  unaffected	  first-­‐degree	  relatives	  (UR)	  of	  the	  recruited	  patients	  
and	  a	  group	  of	  healthy	  control	  subjects	  (HC).	  
	  
Patients	  were	  eligible	  in	  the	  research	  if	  they	  met	  the	  following	  inclusion	  criteria:	  
-­‐ age	  18-­‐55	  
-­‐ specific	   Axis	   I	   disorders,	   according	   to	   DSM-­‐IV	   TR	   criteria	   (APA,	   2000),	  
within	  the	  bipolar-­‐schizophrenic	  spectrum	  (as	  listed	  above)	  
-­‐ illness	  onset	  before	  the	  age	  of	  35	  
-­‐ duration	  of	  illness	  over	  3	  years	  
	  
Control	   subjects	   were	   recruited	   from	   the	   community	   of	   friends	   and	  
acquaintances	   or	   from	   staff,	   and	   were	   matched	   to	   the	   combined	   group	   of	  
patients	  on	  the	  basis	  of	  age	  and	  gender.	  None	  of	  the	  comparison	  subjects	  had	  a	  
personal	   or	   family	   history	   of	   major	   psychiatric	   disorders	   or	   current	   use	   of	  
psychotropic	  medications.	  
	  
Exclusion	  criteria	  for	  all	  the	  groups	  of	  participants	  were:	  
-­‐ presence	  of	  concomitant	  medical	  conditions	  
-­‐ lifetime	  history	  of	  neurological	   illness	  or	  head	   trauma	   leading	   to	   loss	  of	  
consciousness	  for	  more	  than	  5	  minutes	  
-­‐ secondary	  diagnosis	  of	  Delirium,	  Dementia,	  Amnestic	  or	  other	  Cognitive	  
Disorders	  according	  to	  DSM-­‐IV	  TR	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-­‐ DSM-­‐IV	   Substance	  Abuse	   or	   Substance	  Dependence	   disorder	  within	   the	  
previous	  12	  months	  
-­‐ contraindications	  to	  magnetic	  resonance	  scanning	  
	  	  
The	  research	  was	  approved	  by	  the	  relevant	  local	  ethics	  committees	  (Padova	  and	  
Treviso)	  and	  all	  the	  subject	  were	  enrolled	  after	  receiving	  a	  complete	  description	  
of	  the	  study	  procedures	  and	  providing	  written	  informed	  consent.	  
	  
Participation	   in	   the	   research	   has	   been	   proposed	   to	   outpatients	   and	   inpatients	  
referring	   to	   Psychiatry	   Unit	   of	   Conegliano	   and	   Psychiatry	   Clinic	   of	   Padova	  
University.	  A	  total	  of	  101	  patients	  were	  eligible	  and	  screened,	  and	  96	  of	  them	  (70	  
from	  Conegliano	  and	  26	  from	  Padova)	  joined	  the	  study.	  	  
In	   addition,	   a	   little	   group	   of	   10	   unaffected	   first-­‐degree	   relatives	   (8	   from	  
Conegliano	  and	  2	  from	  Padova)	  was	  recruited.	  	  
With	  regard	  to	  healthy	  controls,	  64	  were	  proposed	  to	  participate	  and	  57	  of	  them	  
accepted	  to	  follow	  the	  study.	  
	  
2.2.	  CLINICAL	  ASSESSMENT	  
Psychiatric	   assessment	   was	   carried	   out	   by	   obtaining	   psychiatric	   and	   medical	  
history,	   performing	   a	   mental	   status	   examination	   and	   conducting	   a	   structured	  
Mini	  International	  Neuropsychiatric	  Interview	  (M.I.N.I.)	  (Sheehan	  et	  al.	  1998)	  to	  
determine	   specific	   diagnoses	   according	   to	  DSM-­‐IV	   TR	   criteria.	   The	  M.I.N.I.	  was	  
also	  administered	  in	  the	  control	  group	  to	  rule	  out	  the	  presence	  of	  current	  or	  past	  
psychiatric	  conditions.	  	  
	  
The	  patient	  group,	  basing	  on	  DSM-­‐IV	  TR	  criteria,	   is	  divided	   in:	  49	  patients	  with	  
Schizophrenia	   or	   Schizoaffective	   Disorder,	   6	   patients	   with	   Psychotic	   Disorders	  
Not	   Otherwise	   Specified,	   38	   patients	   with	   Bipolar	   type	   I	   or	   II	   Disorder,	   and	   3	  
patients	  with	  Major	  Depressive	  Disorder.	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Symptoms	   severity	  was	   assessed	  with	   the	   Brief	   Psychiatric	   Rating	   Scale	   (BPRS)	  
(Overall	   and	   Gorham	   1962;	   Ventura	   et	   al.	   1993),	   the	   17-­‐item	   version	   of	   the	  
Hamilton	  Depression	  Rating	  Scale	  (HDRS)	  to	  rate	  depressive	  symptoms	  (Hamilton	  
1960),	  the	  14-­‐item	  Hamilton	  Rating	  Scale	  for	  Anxiety	  (HAS)	  (Hamilton	  1959),	  the	  
Young	  Mania	  Rating	  Scale	   (YMRS)	   for	  manic	  symptoms	  (Young	  et	  al.	  1978),	   the	  
Positive	   and	   Negative	   Syndrome	   Scale	   (PANSS)	   to	   rate	   severity	   of	   psychotic	  
symptoms	   (Kay	   et	   al.	   1987),	   and	   the	   Global	   Assessment	   of	   Functioning	   (GAF)	  
(from	  DSM-­‐IV-­‐TR,	  page	  34).	  
	  
All	   patients	   were	   evaluated	   if	   considered	   clinically	   stable	   (inpatients	   were	  
assessed	   next	   to	   discharge).	   All	   the	   scales	   were	   administered	   on	   the	   day	   that	  
subjects	   underwent	   MRI.	   The	   data	   were	   used	   to	   analyse	   the	   relationships	  
between	   volumetric	   data	   and	   concurrent	   symptom	   state	   and	   severity.	   Age	   at	  
onset	  and	  length	  of	  illness	  (expressed	  in	  years)	  were	  recorded	  during	  the	  clinical	  
assessment.	  
	  
Table	   1	   and	   2	   report	   the	   demographic	   and	   clinical	   characteristics	   of	   the	  
subsample	  of	   subjects,	  which	  were	   recruited	   for	   the	   imaging	   study	   and	  whose	  
ROI	  volumetry	  was	  accomplished	  (see	  below).	  
	  
	  
Table	  1.	  Demographic	  data	  (see	  below).	  
	   SCHIZOPHRENICS	   BIPOLARS	   CONTROLS	   RELATIVES	  
total	  number	   31	   27	   26	   8	  
sex	  
M	   17	   13	   13	   4	  
F	   14	   14	   13	   4	  
age,	  yr	  (m	  ±	  sd)	   37,4	  ±	  8,9	   39,8	  ±	  9,1	   36,6	  ±	  10,6	   37,6	  ±	  7,8	  
edu,	  yr	  (m	  ±	  sd)	   12	  ±	  3,3	   12,8	  ±	  3,2	   15,3	  ±	  2,8	   13,6	  ±	  3,3	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Table	  2.	  Clinical	  data	  (all	  values	  are	  reported	  as	  mean	  ±	  standard	  deviation).	  
	   SCHIZOPHRENICS	   BIPOLARS	  
age	  at	  onset	  (years)	   24,5	  ±	  6,9	   25,4	  ±	  7,1	  
Illness	  duration	  (years)	   12,9	  ±	  6,7	   14,3	  ±	  8,5	  	  
BPRS	   35,6	  ±	  6,2	   30,2	  ±	  3,1	  
HDRS	   9,8	  ±	  3,2	   8,7	  ±	  5,2	  
HAS	   10,9	  ±	  5,1	   9,2	  ±	  4,6	  
YMRS	   	   7,9	  ±	  5,3	  
PANSS	  
POS	   19,5	  ±	  5,4	   	  
NEG	   23,4	  ±	  8,3	   	  
GEN	   46,1	  ±	  12,8	   	  
GAF	   45,4	  ±	  18,3	   56,8	  ±	  13,2	  
	  
	  
2.3.	  MAGNETIC	  RESONANCE	  IMAGING	  
	  
IMAGE	  ACQUISITION	  
A	  total	  of	  104	  subjects	  (64	  patients:	  36	  SZ	  or	  SA,	  27	  BP,	  2MDD;	  8	  unaffected	  first-­‐
degree	   relatives,	   and	   31	   healthy	   controls)	   underwent	  MRI	   scanning	   during	   the	  
study.	  	  
MRI	   acquisitions	  have	  been	  performed	  using	  a	  1.5	   T	  MRI	   scanner	   (Achieva	  XR;	  
Philips	   Medical	   Systems)	   in	   the	   Neuroradiology	   Unit	   of	   Conegliano	   Hospital	  
(ULSS7	  Pieve	  di	  Soligo,	  TV).	  Whole-­‐brain	  T1-­‐weighted	  three-­‐dimensional	   images	  
(magnetization-­‐prepared	   rapidly	   acquired	   gradient-­‐echo,	   MPRAGE)	   were	  
acquired	  in	  the	  sagittal	  plane	  for	  volumetric	  measurements	  (using	  the	  following	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acquisition	  protocol:	  TR	  =	  10	  msec,	  TE	  =	  4	  msec,	  TI	  =	  300	  msec,	   flip	  angle	  =	  8°,	  
slice	  thickness	  =	  1.25	  mm,	  matrix	  size	  =	  256×256×192,	  voxel	  resolution	  1×1×1,25	  
mm).	  Precautions	  were	  taken	  to	  minimize	  subjects’	  motion	  during	  the	  MRI	  scan	  
by	   instructing	  them	  to	  remain	  as	  still	  as	  possible.	  However,	   to	  correct	   for	  head	  
tilt	  or	  positioning,	  sagittal	  images	  were	  aligned	  approximately	  along	  the	  anterior	  
commissure-­‐posterior	  commissure	  line.	  
In	   addition,	   axial	   proton	   density	   and	   T2-­‐weighted	   images	   were	   obtained	   to	  
exclude	   the	   presence	   of	   cerebral	   structural	   abnormalities	   on	   the	  MRI	   scan.	   A	  
board-­‐certified	  neuroradiologist	  reviewed	  all	  scans.	  	  
The	  procedure	  was	  well	  tolerated	  by	  all	  subjects	  and	  no	  sedation	  was	  necessary.	  	  
	  
PROCESSING	  
The	   imaging	  data	  were	   transferred	   from	   the	  MRI	  unit	   to	  a	  PC	  workstation	  and	  
analysed	  using	  the	  semi-­‐automated	  ANALYZE®	  10.0	  software	  (Analyzedirect	  Inc.,	  
Biomedical	  Imaging	  Resource,	  Mayo	  Foundation,	  Rochester,	  Minnesota	  USA).	  
We	   carried	   out	   a	   stereological	   analysis	   to	   measure	  bilateral	   hippocampal	   gray	  
matter	   volume	   (HV)	   and	   total	   cerebral	   volume	   (TCV):	   stereology	   is	   a	   semi-­‐
automated	  method	  whose	  accuracy	  and	  validity	  for	  volume	  estimation	  has	  been	  
reported	   in	   several	   studies	   and	   stereological	   measurements	   yield	   high	  
repeatability	  and	  precision	  (Ronan	  et	  al.	  2006).	  	  
Our	   sampling	  and	  counting	  protocol	  has	  been	  derived	   from	  previous	   reference	  
protocols	  and	  research	  articles	  (see,	  Sheline	  et	  al.	  1996;	  Rametti	  et	  al.	  2007).	  
Coronal	   slices	   were	   sampled	   and	   a	   rigid	   grid	   of	   points,	   with	   random	   starting	  
position	  and	  angle	  of	  deviation	  from	  horizontal,	  was	  then	  superimposed	  on	  the	  
images.	   Selecting	   the	  optimal	  numbers	  of	   slices	  and	  grid	   sizes	  are	  essential	   for	  
assessing	   structurally	   complex	   objects	  whose	  profiles	   change	   significantly	   from	  
slice	  to	  slice.	  Inter-­‐slice	  distance	  and	  grid	  size	  were	  chosen	  to	  yield	  a	  Coefficient	  
of	   Error	   (CE)	   in	   the	  0.01-­‐0.04	   range.	   For	  hippocampal	   gray	  matter	  detection,	   a	  
2×2	   mm2	   rigid	   grid	   was	   superimposed	   on	   every	   third	   coronal	   slice;	   for	   total	  
cerebral	   volume	   a	   10x10	   rigid	   grid	   was	   superimposed	   every	   ten	   coronal	   slice.	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Grid	  points	  falling	  within	  the	  hippocampal	  gray	  matter	  or	  total	  cerebral	  volume	  
were	  counted.	  	  
The	  Orthogonal	  tool	  of	  the	  software	  allows	  three	  orthogonal	  views	  (sagittal,	  axial,	  
and	  coronal)	  of	  each	  grid	  at	   the	   same	   time,	   thus	  enabling	   the	   raters	   to	  decide	  
more	  accurately	  which	  cross	  is	  included	  in	  the	  hippocampal	  o	  cerebral	  structure:	  
(see	   Fig.	   5,	   7,	   9	   and	   11).	   This	   provides	   greater	   clarity	   of	   anatomic	   localization.	  
Two	   raters,	   who	   were	   blind	   to	   subject	   identity	   and	   clinical	   characteristics,	  
performed	  all	  the	  measurement	  procedures	  for	  the	  selected	  regions	  of	  interest.	  	  
	  
Anatomical	   boundaries,	   according	   to	   brain	   atlases	   (Duvernoy	   1988)	   and	  
neuroimaging	  literature,	  were	  defined	  as	  follows:	  
-­‐	  Total	  Cerebral	  volume	  (Fig.	  4	  and	  5).	  All	  brain	  tissue	  of	  the	  cerebral	  hemispheres	  
(both	  gray	  and	  white	  matter),	   including	  the	  midbrain	  superior	  to	  the	  pons.	  The	  
superior	  border	  of	  the	  pons	  was	  chosen	  as	  the	  point	  of	  demarcation	  because	  it	  is	  
easily	   recognizable	   (Sheline	   et	   al.	   1996).	   Cerebellum,	   optic	   nerve,	   tracts	   and	  
chiasm,	  and	  cerebrospinal	  fluid	  were	  excluded.	  
	  
	  




Figure	  5.	  Same	  cerebral	  portion,	  in	  the	  3	  orthogonal	  axes.	  
	  
-­‐	  Hippocampal	   formation	   (Fig.	   6-­‐11).	   For	   the	  anterior	  boundary	   the	  alveus	  was	  
used	   as	   a	   border	   between	   amygdala	   and	   hippocampus	   (Pantel	   et	   al.	   2000;	  
Rametti	   et	   al.	   2007).	   Posteriorly,	   the	   tail	   of	   the	   hippocampus	   continues	   as	   the	  
indusium	  griseum,	  a	  thin	  strip	  of	  gray	  matter	  overlying	  the	  surface	  of	  the	  corpus	  
callosum.	  For	  purposes	  of	  measurement,	  the	  posterior-­‐most	  slice	  for	  volumetry	  
was	  defined	  as	  the	  slice	  where	  the	  hippocampus	  first	  appeared	  adjacent	  to	  the	  
trigone	   of	   the	   lateral	   ventricle	   (Sheline	   et	   al.	   1996;	   Sheline	   et	   al.	   2012).	  
Volumetrically	   included	   tissues	   were	   an	   elongated	   gray	   matter	   complex	  
bordered	   superiorly	   by	   the	   fornix-­‐fimbria	   white	   matter	   junction,	   inferiorly	   by	  
parahippocampal	   gyrus	   white	   matter,	   medially	   by	   the	   subarachnoid	   spaces	   of	  
various	   cisterns	   (e.g.,	   ambient	   cistern),	   and	   laterally	  by	   the	   cerebrospinal	   fluid-­‐
filled	   lateral	   ventricle.	   The	   gray	   matter	   complex	   included	   the	   cornu	   ammonis,	  
dentate	   gyrus,	   and	   subiculum.	   The	   vertical	   digitation	   of	   the	   head	   of	   the	  
hippocampus,	  which	  curves	  up	  and	  medial	  to	  the	  amygdala	   in	  coronal	  sections,	  
was	   included.	   Volumetrically	   excluded	   tissues	   were	   the	   fornix-­‐fimbria	   white	  
matter	   complex,	   the	   alveus,	   the	   white	   matter	   of	   the	   parahippocampal	   gyrus,	  
various	  fluid-­‐filled	  spaces	  including	  ventricles,	  subarachnoid	  spaces	  and	  sporadic	  
fluid-­‐density	  spaces	  in	  the	  hippocampus	  complex,	  and	  the	  amygdala	  proper	  and	  
the	  white	  matter	  border	  with	  it	  (Sheline	  et	  al.	  1996).	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Figure	  6.	  Hippocampal	  formation	  (head),	  in	  the	  coronal	  plane.	  
	  
	  





Figure	  8.	  Hippocampal	  formation	  (body),	  in	  the	  coronal	  plane.	  
	  
	  
Figure	  9.	  Hippocampal	  formation	  (body),	  in	  the	  3	  orthogonal	  axes.	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Figure	  10.	  Hippocampal	  formation	  (tail),	  in	  the	  coronal	  plane.	  
	  
	  





Based	  on	  the	  number	  of	  selected	  grid	  points,	  a	  volume	  estimate	  is	  extrapolated	  
by	  the	  software.	  Each	  region	  of	  interest	  (ROI)	  volume	  is	  then	  calculated	  applying	  
the	   specific	   Statistics	   tool	   of	   ANALYZE	   software:	   the	   resulting	   values	   are	  
expressed	  in	  mm3.	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We	  calculate	  bilateral	  hippocampal	  volume	  (HV)	  and	  total	  cerebral	  volume	  (TCV)	  
in	  a	  sample	  of	  31	  schizophrenic	  patients,	  27	  bipolar	  patients,	  8	  unaffected	  first-­‐
degree	  relatives	  and	  26	  healthy	  controls.	  
	  
2.4.	  STATISTICAL	  ANALYSIS	  
To	   verify	   the	   normal	   distribution	   of	   our	   variables	  we	   applied	   the	   Kolmogorov-­‐
Smirnov	  test	  or	  the	  Shapiro-­‐Wilk	  test,	  whereas	  the	  Levene’s	  test	  was	  performed	  
to	  evaluate	  the	  homogeneity	  of	  variances	  in	  the	  different	  samples.	  	  With	  respect	  
to	   ROI	   volumes	   of	   patients	   and	   controls,	   all	   the	   data	   demonstrated	   a	   normal	  
distribution	  (see,	  as	  examples,	  Fig.	  12	  and	  13).	  	  
To	   compare	   mean	   values	   between	   groups	   we	   used	   Student’s	   t-­‐test	   for	  
independent	  samples	  if	  normality	  of	  distributions	  and	  equality	  of	  variances	  were	  
confirmed,	  and	  Welch’s	  t-­‐test	  variant	  when	  homoscedasticity	  was	  not	  assumed.	  
For	   comparison	   between	   non-­‐normal	   variables,	   and	   to	   compare	   data	  with	   the	  
small	  sample	  of	  unaffected	  first-­‐degree	  relatives,	  we	  applied	  the	  non-­‐parametric	  
Mann-­‐Whitney	  U	  test.	  	  	  
	  
	  
Figure	  12.	  Right	  Hippocampus	  (HIPPO.DX	  in	  the	  picture)	  in	  the	  Schizophrenic	  and	  Bipolar	  group.	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Figure	   13.	   Left	  Hippocampus	   (HIPPO.SX	   in	   the	  picture)	   in	   the	  Control	  group	  and	  Total	  Cerebral	  
Volume	  (VCT	  in	  the	  picture)	  in	  the	  Bipolar	  group.	  
	  
An	   inter-­‐rater	  and	   intra-­‐rater	  reliability	  study	  was	  carried	  out	  by	  the	  two	  raters	  
who	  calculated	  hippocampal	  gray	  matter	  (HV)	  and	  total	  cerebral	  volumes	  (TCV)	  
and	  Intraclass	  Correlation	  Coefficients	  (ICC)	  were	  then	  calculated.	  For	  the	  inter-­‐
rater	   reliability,	   ICC	   resulted	   0.94	   for	   TCV,	   0.90	   and	   0.91	   for	   right	   and	   left	   HV	  
respectively;	  intra-­‐rater	  correlation	  coefficients	  were	  calculated	  for	  right	  (for	  the	  
2	   raters	   respectively	   0.94	   and	   0.96)	   and	   left	   (0.96	   and	   0.97)	   hippocampal	   gray	  
matter	   volumes	   and	   for	   total	   cerebral	   volumes	   (0.96	   and	   0.96).	   The	   overall	  
coefficient	  of	  error	  (CE)	  was	  0.02.	  
	  
To	   correct	   for	   individual	   variations	   in	   head	   size,	   we	   normalized	   the	   calculated	  
hippocampal	  volumes	  by	  performing	  a	   ratio	  with	   total	   cerebral	  volumes	   (HV	   in	  
mm3/TCV	  in	  mm3	  x	  100),	  as	  described	  in	  literature	  (Free	  et	  al.	  1995;	  Whitwell	  et	  
al.	  2001;	  Rametti	  et	  al.	  2007).	  
	  
Descriptive	   statistics	   and	   comparison	   analysis	   were	   performed	   by	   using	   SPSS	  
software,	  version	  16.0:	  all	  the	  tests	  were	  two-­‐tailed	  and	  the	  level	  of	  significance	  




3.1.	  DEMOGRAFIC	  AND	  CLINICAL	  DATA	  
Our	  analysis	  did	  not	  report	  any	  statistically	  significant	  difference	  with	  respect	  to	  
age	   between	   Schizophrenics	   (t=-­‐,33;	   p=,73)	   or	   Bipolars	   (t=-­‐1,21;	   p=,22)	   and	  
controls,	  neither	  between	  schizophrenic	  and	  bipolar	  patients	  (t=1,04;	  p=,30),	  nor	  
between	  the	  unaffected	  relatives	  and	  the	  control	  group	  (Z=-­‐0,38;	  p=,70).	  
No	   statistically	   significant	   differences	  were	  noticed	   in	   education	   level	   between	  
the	  two	  patient	  groups	  (Z=-­‐1,14;	  p=,30)	  or	  between	  the	  unaffected	  relatives	  and	  
the	   healthy	   controls	   (Z=-­‐1,45;	   p=,14);	   education	   level	   differed	   significantly	  
between	  the	  schizophrenic	  group	  (Z=-­‐4,12;	  p<,05)	  or	  the	  bipolar	  group	  (Z=-­‐2,93;	  
p<,05)	  compared	  to	  the	  healthy	  controls.	  
	  
Patients’	   between-­‐group	   comparison	   did	   not	   reveal	   statistically	   significant	  
differences	   with	   respect	   to	   age	   at	   onset	   (t=,49;	   p=,62)	   and	   total	   duration	   of	  
illness	  (t=,78;	  p=,43).	  
With	   regard	   to	   symptoms	   severity,	   the	   respective	   scores,	   when	   directly	  
comparable,	   did	   not	   differ	   between	   schizophrenic	   and	   bipolar	   patients	   (for	  
HDRS:	  t=,96;	  p=,35;	  for	  HAS:	  t=1,03;	  p=,31;	  for	  BPRS:	  Z=-­‐,59;	  p=,60).	  
3.2.	  VOLUMETRIC	  DATA	  
Results	   from	   the	   volumetric	   comparison	   analysis	   between	   the	  different	   groups	  
are	  reported	  in	  the	  following	  tables	  (see	  also	  Fig.	  14-­‐16).	  
	  
Right	   and	   left	   hippocampi	   demonstrated	   a	   statistically	   significant	   reduction	   in	  
gray	  matter	   volume	   in	   the	   two	  patient	   groups	   compared	   to	   the	   control	   group.	  
With	   respect	   to	   total	   cerebral	   volume,	   schizophrenic	   patients	   reached	  
statistically	   significant	   reduction,	   whereas	   bipolar	   patients’	   total	   cerebral	  
volumes	  did	  not	  differ	  significantly	  from	  the	  controls’	  ones	  (Tab.	  3	  and	  4).	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Table	  3.	  Volumetric	  (mean	  ±	  sd)	  comparison	  between	  Schizophrenics	  and	  Controls.	  
	  
VOLUMES	  (mm3)	   t-­‐test	  






3,94	   <	  ,00	  
right	  HIPPO	   2021,02	  ±	  191,47	   2769,20	  ±	  336,90	   10,9	   <	  ,00	  
left	  HIPPO	   1970,78	  ±	  243,09	   2696,28	  ±	  312,51	   10,6	   <	  ,00	  
right	  HIPPO/TCV	   0,2246	  ±	  0,026	   0,2756	  ±	  0,036	   6,58	   <	  ,00	  
left	  HIPPO/TCV	   0,2184	  ±	  0,026	   0,2684	  ±	  0,035	   6,65	   <	  ,00	  
	  
Table	  4.	  Volumetric	  (mean	  ±	  sd)	  comparison	  between	  Bipolars	  and	  Controls.	  
	  
VOLUMES	  (mm3)	   t-­‐test	  






1,69	   ,09	  
right	  HIPPO	   2143,42	  ±	  286,17	   2769,20	  ±	  336,90	   7,56	   <	  ,00	  
left	  HIPPO	   1978,89	  ±	  184,75	   2696,28	  ±	  312,51	   10,4	   <	  ,00	  
right	  HIPPO/TCV	   0,2250	  ±	  0,034	   0,2756	  ±	  0,036	   5,37	   <	  ,00	  
left	  HIPPO/TCV	   0,2077	  ±	  0,025	   0,2684	  ±	  0,035	   7,46	   <	  ,00	  
	  
In	   the	   direct	   comparison	   between	   schizophrenic	   and	   bipolar	   patients,	   we	  
identified	   statistically	   significant	   gray	   matter	   volume	   reduction	   in	   the	  
schizophrenics’	  right	  hippocampus,	  but	  no	  significant	  between-­‐group	  differences	  
for	   left	   hippocampus	   or	   total	   cerebral	   volume.	   However	   statistical	   significance	  
was	  lost	  after	  normalization	  (Tab.	  5).	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Table	  5.	  Volumetric	  (mean	  ±	  sd)	  comparison	  between	  Schizophrenics	  and	  Bipolars.	  
	  
VOLUMES	  (mm3)	   t-­‐test	  






1,96	   ,054	  
right	  HIPPO	   2021,02	  ±	  191,47	   2143,42	  ±	  286,17	   2,03	   ,046	  
left	  HIPPO	   1970,78	  ±	  243,09	   1978,89	  ±	  184,75	   0,14	   ,885	  
right	  HIPPO/TCV	   0,2246	  ±	  0,026	   0,2250	  ±	  0,034	   0,04	   ,962	  




Figure	   14.	   Total	   cerebral	   volumes	   (VCT	   in	   the	   picture)	   in	   the	   different	   groups	   (in	   the	   picture	  
FM=unaffected	  relatives,	  CTRL=healthy	  controls).	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Table	  6.	  Volumetric	  (mean	  ±	  sd)	  comparison	  between	  Unaffected	  Relatives	  and	  Controls.	  
	  
VOLUMES	  (mm3)	   Mann-­‐Whitney	  






-­‐0,10	   ,91	  
right	  HIPPO	   2550,92	  ±	  251,51	   2769,20	  ±	  336,90	   -­‐1,80	   ,07	  
left	  HIPPO	   2450,37	  ±	  173,36	   2696,28	  ±	  312,51	   -­‐2,57	   ,01	  
right	  HIPPO/TCV	   0,2519	  ±	  0,030	   0,2756	  ±	  0,036	   -­‐1,70	   ,08	  
left	  HIPPO/TCV	   0,2427	  ±	  0,032	   0,2684	  ±	  0,035	   -­‐1,80	   ,07	  
	  
	  
Comparison	  analysis	  between	  the	  unaffected	  first-­‐degree	  relatives	  and	  the	  same	  
control	   group	   (Tab.	   6)	   revealed	   a	   statistically	   significant	   gray	   matter	   volume	  
reduction	  in	  the	  left	  hippocampus	  and	  a	  trend	  towards	  statistical	  significance	  for	  
right	  hippocampus;	  furthermore	  a	  trend	  towards	  statistically	  significant	  bilateral	  
reduction	  in	  hippocampal	  gray	  matter	  volumes	  persisted	  after	  normalization.	  	  
No	   statistically	   significant	   differences	   in	   total	   cerebral	   volumes	   where	   found	  










Figure	   15.	  Right	  hippocampal	  volumes	   (HIPPO.DX	   in	   the	  picture)	   in	   the	  different	  groups	   (in	   the	  
picture	  FM=unaffected	  relatives,	  CTRL=healthy	  controls).	  
	  
	  
Figure	   16.	   Left	   hippocampal	   volumes	   (HIPPO.SX	   in	   the	   picture)	   in	   the	   different	   groups	   (in	   the	  
picture	  FM=unaffected	  relatives,	  CTRL=healthy	  controls).	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4.	  DISCUSSION	  AND	  CONCLUSIONS	  
In	   the	   present	   study	   we	   aimed	   to	   investigate	   the	   presence	   of	   volumetric	  
differences	  in	  gray	  matter	  hippocampal	  volumes	  and	  total	  cerebral	  volumes	  in	  a	  
group	  of	  patients	  suffering	  from	  bipolar-­‐schizophrenic	  spectrum	  disorders	  and	  in	  
a	   little	   group	   of	   unaffected	   fist-­‐degree	   relatives,	   in	   comparison	   with	   matched	  
healthy	  control	  subjects.	  
	  
We	   identified	   statistically	   significant	   reductions	   in	   bilateral	   gray	   matter	  
hippocampal	   volumes	   and	   total	   cerebral	   volumes	   in	   the	   schizophrenic	  patients	  
compared	  to	  healthy	  subjects.	  Our	  data	  are	  in	  line	  with	  the	  majority	  of	  research	  
papers,	   reviews	  and	  meta-­‐analysis,	  which	  demonstrate	  significant	   reductions	   in	  
hippocampal	  and	  total	  cerebral	  volumes	  in	  first-­‐episode	  or	  chronic	  schizophrenia,	  
and	  also	  individuals	  at	  high	  risk	  for	  schizophrenia	  (Steen	  et	  al.	  2006;	  Wright	  et	  al.	  
2000;	   Shenton	  et	   al.	   2001;	   Pantelis	   et	   al.	   2005;	  Honea	  et	   al.	   2005;	  Olabi	   et	   al.	  
2011;	  Chan	  et	  al.	  2011).	  
In	  literature,	  there	  is	  lot	  of	  interest	  concerning	  brain	  anomalies	  in	  Schizophrenia	  
and,	   particularly,	   if	   such	   alterations	   in	   morphology	   and	   connectivity	   are	  
expressions	   of	   neurodevelopmental	   or	   neurodegenerative	   phenomena	   (or	  
possibly	  both	  of	  them).	  
It	   has	   been	   postulated	   that	   early	   (pre-­‐	   and	   perinatal)	   neurodevelopmental	  
lesions	   (e.g.,	   viral	   infections	   during	   pregnancy	   or	   obstetric	   complications)	  
(McNeil,	   Cantor-­‐Graae,	   and	   Ismail	   2000)	   render	   the	   brain	   vulnerable	   to	  
anomalous	   late	   (particularly	   post-­‐pubertal)	   neurodevelopmental	   processes	   (for	  
example,	   the	   so-­‐called	   “extended	   pruning”),	   and	   these	   anomalous	  
neurodevelopmental	  processes	   interact	  with	  other	   causative	   factors	  associated	  
with	  the	  onset	  of	  psychosis	  (e.g.,	  substance	  use,	  stress,	  and	  dysregulation	  of	  the	  
HPA	   axis	   function),	   which	   together	   have	   neuroprogressive	   sequelae	   involving	  
medial	  temporal	  and	  prefrontal	  regions	  (Pantelis	  et	  al.	  2005).	  	  
Excess	   glucocorticoids	   cause	   retraction	   and	   simplification	   of	   dendrites	   in	   the	  
hippocampus	   and	   this	   morphological	   change	   probably	   accounts	   for	   the	  
hippocampal	  volume	  loss.	  Mechanisms	  by	  which	  glucocorticoids	  affect	  the	  brain	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include	   decreased	   neurogenesis	   and	   synthesis	   of	   neurotrophic	   factors	   (BDNF),	  
impaired	   glucose	   utilization	   (given	   the	   Dentate	   Gyrus	   sensitivity	   to	  
hypoglycemia),	   and	   increased	   actions	   of	   excitatory	   amino	   acids	   (glutamate)	   in	  
CA3	  pyramidal	  neurons	  (Yusim	  et	  al.	  2000;	  Szeszko	  et	  al.	  2006;	  Patil	  et	  al.	  2007;	  
Toffanin	  et	  al.	  2011).	  
According	   to	   Andreasen	   and	   colleagues,	   some	   schizophrenic	   patients	   are	  
undergoing	   a	   process	   of	   progressive	   brain	   change,	   defined	   as	   a	   decrement	   in	  
brain	   tissue	   volume	   that	   is	   occurring	   at	   a	   more	   rapid	   rate	   in	   patients	   than	   in	  
control	   subjects.	   Thus,	   schizophrenia	   has	   a	   “neuroprogressive”	   component,	  
defined	  as	  tissue	  volume	  decrease	  occurring	  after	  onset.	  The	  gray	  mater	   loss	   is	  
consistent	  with	  the	  known	  neuropathology	  of	  the	  illness,	  which	  involves	  cortical	  
thinning,	  due	  primarily	  to	  shrinkage	  in	  neuropil,	  and	  without	  either	  the	  neuronal	  
loss	   or	   gliosis	   that	   characterize	   neurodegenerative	   processes.	   Another	  
mechanism	  that	  may	  explain	  the	  gray	  matter	  decreases	  occurring	  after	  the	  onset	  
of	   schizophrenia	   is	   diminished	   neuroplasticity,	   an	   impairment	   in	   activity-­‐
dependent	   neuroplasticity	   that	   affects	   spines	   and	   synapses,	   leading	   to	   a	  
shrinkage	  of	  neuropil	  (Andreasen	  et	  al.	  2011).	  	  
	  
Unexpectedly,	  our	  study	  found	  bilateral	  hippocampal	  gray	  matter	  reduction	  also	  
in	  the	  bipolar	  group,	  compared	  to	  healthy	  controls.	  	  
In	   literature,	   with	   regard	   to	   hippocampal	   volumes,	   data	   emerging	   from	   ROI-­‐
based	   or	   VBM	   studies	   are	   extremely	   variable:	   the	   majority	   of	   them	   failed	   to	  
detect	   significant	   volume	   differences	   between	   bipolar	   patients	   and	   healthy	  
controls	  (Hauser	  et	  al.	  2000;	  Altshuler	  et	  al.	  2000;	  Brambilla	  et	  al.	  2003;	  Strasser	  
et	  al.	  2005;	  Adler	  et	  al.	  2007;	  Lim	  et	  al.	  2013).	  According	  to	  Frey	  and	  colleagues,	  
the	  possibility	  that	  only	  specific	  subtypes	  of	  bipolar	  disorder	  are	  associated	  with	  
structural	  brain	  abnormalities	  might,	  at	  least	  to	  some	  extent,	  explain	  the	  lack	  of	  
positive	  findings	  of	  hippocampal	  volume	  changes	  in	  the	  disease	  (Frey	  et	  al.	  2007).	  
Nevertheless,	   some	  studies	   support	   the	  existence	  of	   volumetric	   changes	   in	   the	  
hippocampus	  of	  BD	  patients.	  For	  instance,	  Swayze	  and	  colleagues,	  comparing	  48	  
bipolar	   patients	   to	   47	   healthy	   controls,	   found	   that	   the	   right	   hippocampus	  was	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significantly	   smaller	   in	   patients,	   particularly	   in	   men	   (Swayze	   et	   al.	   1992).	  
Differences	   in	   hippocampal	   volume	   were	   also	   found	   in	   studies	   focusing	   on	  
pediatric,	  as	  well	  as	  on	  older,	  bipolar	  patients.	  Blumberg	  et	  al.	  (2003)	  studied	  36	  
bipolar	  type	  I	  patients	  (14	  adolescents	  and	  22	  adults)	  and	  56	  healthy	  controls	  (23	  
adolescents	  and	  33	  adults).	  Considering	  adolescents	  and	  adults	   together,	   there	  
was	   a	   decrease	   of	   5.3%	   in	   bilateral	   hippocampal	   volumes	   in	   bipolar	   patients,	  
although	   this	   difference	   did	   not	   reach	   statistical	   significance.	   An	   age-­‐group	  
comparison	  (BD	  adolescents	  versus	  HC	  adolescents),	  nevertheless,	  showed	  that	  
hippocampal	  volume	  was	  significantly	  decreased	  in	  bipolar	  adolescents,	  whereas	  
this	  difference	  was	  not	  observed	  between	  adult	  bipolars	   versus	   adult	   controls.	  
Frazier	  and	  colleagues	  compared	  43	  adolescents	  suffering	  from	  bipolar	  disorder	  
with	   20	   healthy	   controls	   and	   found	   that	   bipolar	   patients	   had	   smaller	  
hippocampal	   volumes,	   and	   this	   effect	   was	   predominantly	   driven	   by	   female	  
gender	  (Frazier	  et	  al.	  2005).	  
Recently,	   Chepenik	   and	   colleagues	   reported	   hippocampal	   decrease	   in	   two	  
different	   studies	   comparing	   bipolar	   patients	   and	   healthy	   controls.	   They	   found	  
that	   hippocampal	   volumes	   were	   significantly	   smaller	   in	   bipolar	   compared	   to	  
control	  subjects	  and,	  analyzing	  the	  BDNF	  val66met	  polymorphism,	  the	  presence	  
of	  the	  BDNF	  met	  allele	  was	  associated	  with	  smaller	  hippocampal	  volumes	  in	  both	  
diagnostic	   groups:	   moreover	   the	   bipolar	   subgroup	   who	   carried	   the	   BDNF	  met	  
allele	  had	  the	  smallest	  hippocampi	  (Chepenik	  et	  al.	  2009;	  2012).	  
In	   a	   recent	   study,	   comparing	   patients	   with	   borderline	   personality	   disorder,	  
patients	   with	   bipolar	   disorder	   and	   healthy	   controls,	   Rossi	   and	   colleagues	  
reported	   that	   the	  bipolar	  group	  showed	  significantly	   smaller	   right	  hippocampal	  
volume	  compared	   to	   the	  control	  group:	   specifically,	  using	  3D	  surface	  mapping,	  
alterations	  were	  localized	  in	  the	  right	  dentate	  gyrus	  (Rossi	  et	  al.	  2012).	  
In	  line	  with	  the	  above	  findings,	  it	  could	  be	  speculated	  that	  hippocampal	  volume	  
reduction	  in	  bipolar	  disorder	  —	  likewise	  in	  recurrent	  major	  depression	  (Nifosì	  et	  
al.	   2010)	   —	   may	   be	   due	   to	   chronic	   stress	   response.	   Actually,	   dentate	   gyrus-­‐
dependent	   inhibition	   of	   the	   stress	   response	   plays	   an	   important	   role	   in	   mood	  
disorders.	   During	   stress,	   hippocampal	   projections	   traversing	   the	   fimbria	   inhibit	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the	  HPA	  axis.	  A	  very	  recent	  study,	  aiming	  to	  measure	  the	  volumes	  of	  the	  Dentate	  
Gyrus,	  Cornu	  Ammonis	  and	  fimbria	  in	  patients	  with	  Bipolar	  Disorder	  type	  II	  and	  
healthy	  controls,	  reported	  a	  smaller	  left	  CA2-­‐3	  volume	  in	  bipolar	  subjects	  and	  a	  
reduced	   left	   fimbria	   volume	   in	   unmedicated	   patients	   compared	   to	   medicated	  
patients	  and	  controls	  (Elvsåshagen	  et	  al.	  2013).	  
Various	  neuropathological	  post	  mortem	  studies	   support	   the	   thesis	  of	  a	   specific	  
hippocampal	   involvement	   in	   Bipolar	   Disorder.	   Benes	   and	   colleagues	   found	  
decreased	   number,	   density,	   and	   size	   of	   nonpyramidal	   neurons	   in	   CA2	   and	   a	  
similar	  trend	  in	  the	  CA3	  region	  (Benes	  et	  al.	  1998);	  Liu	  et	  al.	  stained	  hippocampal	  
tissue	  sections	  from	  CA1	  area,	  and	  found	  that	  BD	  patients	  had	  a	  significant	  12%	  
reduction	  in	  pyramidal	  somal	  size	  (Liu	  et	  al.	  2007).	  Other	  morphological	  studies	  
suggest	   that	   GABAergic	   and	   glutamatergic	   abnormalities	   might	   take	   place	   in	  
discrete	   subregions	   of	   the	   hippocampal	   formation	   in	   individuals	   with	   bipolar	  
disorder	   (Frey	  et	   al.	   2007).	  Heckers	   and	   colleagues	   found	  decreased	  density	  of	  
GAD	  (glutamic	  acid	  decarboxylase)	  65	  and	  GAD	  67	  mRNA-­‐positive	  neurons	  in	  the	  
hippocampus	   of	   bipolars,	   suggesting	   changes	   in	   GABA	   synthesis	   or	   loss	   of	  
GABAergic	   cells	   (Heckers	   et	   al.	   2002).	   Physiologically,	   hippocampal	   GABAergic	  
interneurons	   play	   a	   critical	   role	   in	   feedback	   and	   feedforward	   inhibitory	  
mechanisms,	   thereby	   controlling	   the	   excitability	   of	   pyramidal	   neurons,	   to	  
coordinate	   neuronal	   transmission	   and	   avoid	   excessive	   firing	   (Buzsáki	   1997).	  
Disruption	   of	   hippocampal	   GABAergic	   and	   glutamatergic	   neurotransmission	  
might	   lead	   to	   abnormal	   brain	   responses	   to	   stress	   (McEwen	   1999).	   Conversely,	  
the	   hippocampus	   is	   particularly	   vulnerable	   to	   damage	   after	   repeated	   stress	  
(Sapolsky	  1996).	  	  
These	   above	   described	   studies	   further	   indicate	   that	   bipolar	   disorder	  might	   be	  
associated	  with	   abnormal	   glutamatergic	   transmission	   and	   synaptic	   plasticity	   in	  
the	   hippocampus	   and	   its	   closely	   related	   regions.	   In	   each	   of	   the	   four	   cornu	  
ammonis	   sectors	   (CA1-­‐4)	   of	   the	   hippocampus,	   GABAergic	   interneurons	   are	  
interspersed	  with	  a	  much	  larger	  number	  of	  gutamatergic	  principal	  neurons,	  but	  a	  
single	   interneuron	   provides	   inhibition	   through	   1000	   to	   2000	   synapses	   with	  
principal	  neurons.	  Hippocampal	  GABAergic	  neurons	  are	  classified	  basing	  on	   the	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expression	   of	   calcium-­‐binding	   proteins,	   such	   as	   parvalbumin,	   calbindin,	   and	  
calretinin,	   and	   neuromodulators,	   such	   as	   somatostatin,	   neuropeptide	   Y,	  
vasoactive	  intestinal	  peptide,	  and	  nitric	  oxide	  synthase.	  	  These	  “markers”	  identify	  
subtypes	  of	  hippocampal	  interneurons	  with	  distinct	  morphological,	  physiological,	  
and	   molecular	   properties.	   Konradi	   and	   colleagues	   demonstrate	   that	   there	   is	  
strong	   evidence	   for	   a	   marked	   reduction	   of	   somatostatin-­‐	   and	   parvalbumin-­‐
positive	   interneurons	   in	   bipolar	   disorder.	   They	   claim	   that	   the	   finding	   of	  
significantly	  reduced	  nonpyramidal	  cell	  layer	  volume	  in	  bipolar	  disorder	  provides	  
compelling	  evidence	  for	  a	  subtle	  volume	  difference	  of	  the	  hippocampus,	  beyond	  
the	   resolution	   of	   current	   imaging	   studies.	   Given	   the	   reduced	   number	   of	  
immunopositive	   interneurons	   they	   interpret	   the	   pattern	   of	   volume	   change	  
observed	   in	   the	   subjects	   with	   bipolar	   disorder	   as	   further	   support	   for	  
hippocampal	  interneuron	  pathology	  in	  bipolar	  disorder	  (Konradi	  et	  al.	  2011).	  	  
Rajkowska	  pointed	  out	   that	   the	  neuropathological	   changes	  observed	   in	  Bipolar	  
Disorder	   resemble	   neurodevelopmental	   rather	   than	   neurodegenerative	  
pathology	   (Rajkowska	   2003).	   This	   assumption	   is	   in	   accordance	   with	   recent	  
reports	   showing	   reduced	   hippocampal	   reelin,	   a	   protein	   that	   is	   involved	   in	  
neuronal	  migration	  during	  brain	  development	  (Knable	  et	  al.	  2004).	  
Konradi	   et	   al.	   (2011)	   did	   also	   observe	   a	   significant	   decrease	   in	   the	   size	   of	  
hippocampal	   neurons,	  most	   pronounced	   in	   sector	   CA2-­‐3,	   in	   line	  with	   a	   similar	  
report	   of	   decreased	   pyramidal	   cell	   size	   in	   CA1	   in	   bipolar	   disorder.	   They	   argue	  
that	   the	  somal	   size	  of	  adult	  hippocampal	  neurons	  could	  be	  a	  distal	   read-­‐out	  of	  
neurodevelopmental	   abnormalities	   or	   a	   more	   proximal	   consequence	   of	  
malfunction	   of	   trophic	   factors	   and	   synaptic	   remodeling	   during	   adulthood.	   Risk	  
genes	  associated	  with	  psychotic	  disorders,	  including	  DISC1	  and	  neuregulin,	  have	  
been	  associated	  with	  regulation	  of	  neuronal	  size	  (Duan	  et	  al.	  2007;	  Krivosheya	  et	  
al.	   2008).	  	   In	   line	   with	   the	   previously	   described	   evidences	   in	   relation	   to	  
schizophrenia,	   there	   is	   converging	   evidence	   demonstrating	   that	   hippocampal	  
impairment	   is	   present	   early	   in	   the	   course	   of	   Bipolar	   disorder,	   suggesting	   that	  
such	   changes	   are	   more	   likely	   to	   be	   related	   to	   constitutive	   —	   genetic	   or	  
neurodevelopmental	  —	  rather	  than	  to	  chronicity	  or	  to	  treatment	  effects.	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In	  contrast	  with	  our	  preliminary	  data,	  when	  directly	  comparing	  the	  two	  separate	  
groups	  of	  patients,	  we	  only	  found	  a	  moderate	  statistically	  significant	  difference	  
in	   schizophrenics’	   right	   hippocampus,	   and	   such	   significance	   was	   lost	   after	  
normalization.	   Even	   if	   both	   schizophrenic	   and	   bipolar	   patients	   demonstrated	  
statistically	   significant	   reductions	   in	   bilateral	   hippocampal	   gray	   matter	   when	  
compared	   to	   healthy	   control	   subjects,	   they	   did	   not	   reveal	   marked	   specific	  
differences	  when	  compared	  to	  each	  other.	  
Although	   it’s	   quite	   recognized	   that	   Schizophrenia	   and	   Bipolar	   disorder	   have	   a	  
number	   of	   overlapping	   symptoms	   and	   risk	   factors,	   it	   is	   not	   yet	   clear	   if	   the	  
disorders	   are	   characterized	   by	   similar	   deviations	   in	   brain	   morphometry	   or	  
whether	  any	  such	  deviations	  reflect	  the	  impact	  of	  shared	  susceptibility	  genes	  on	  
brain	  structure.	  Different	  meta-­‐analysis	  reported	  that	  the	  areas	  of	  reduced	  gray	  
matter	   observed	   in	   studies	   of	   bipolar	   patients	   overlapped	   substantially	   with	  
areas	   of	   reduced	   gray	  matter	   in	   schizophrenia	   patients,	   though	   the	   reductions	  
seen	  bilaterally	  in	  the	  hippocampal-­‐amygdala	  area	  among	  schizophrenia	  patients	  
were	   not	   observed	   in	   bipolar	   patients	   (Ellison-­‐Wright	   and	   Bullmore	   2010)	   and	  
the	   latters	   demonstrated	   enlarged	   amygdala	   volumes	   (Arnone	   et	   al.	   2009).	  
Studies	   in	   literature	   may	   be	   contradictory	   because	   of	   between-­‐study	  
heterogeneity	  in	  the	  patient	  and	  control	  groups	  in	  terms	  of	  medication	  use	  and	  
demographic	  and	  clinical	  variables.	  	  
There	  is	  good	  evidence	  to	  suggest	  medication	  may	  affect	  brain	  structure:	  cross-­‐
sectional	  and	  longitudinal	  studies	  have	  suggested	  lithium	  increased	  gray	  matter	  
volume	   (particularly	   in	   the	   hippocampus)	   possibly	   through	   its	   neurotrophic	  
effects	  (Kempton	  et	  al.	  2008).	  The	  impact	  of	  drugs	  on	  brain	  structures	  is	  a	  matter	  
of	  debate	  (Germaná	  et	  al.	  2010).	  However,	   it	   is	  not	  clear	  whether	  the	  potential	  
effect	   on	  brain	  morphology	   is	   stable	   over	   time	  or	   reversible	   after	   switching	  or	  
discontinuing	  medications.	   In	   neuroimaging	   studies,	   the	   potential	   confounding	  
effect	   of	   medications	   is	   a	   major	   issue	   and	   this	   is	   especially	   problematic	   for	  
studies	  of	  complex	  forms	  of	  pathology	  such	  as	  Schizophrenia	  or	  Bipolar	  Disorder,	  
in	  which	   the	  majority	   of	   individuals	  may	   be	   receiving	   psychotropic	  medication	  
(Phillips	  et	  al.	  2008;	  Hafeman	  et	  al.	  2012;	  Hajek	  et	  al.	  2012).	  We	  could	  speculate	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that	  negative	  findings	  in	  literature	  may	  be	  also	  due	  to	  the	  confounding	  factor	  of	  
lithium	  o	  anticonvulsivants	  medication.	  
	  Similarly	  to	  Brown	  and	  colleagues’	  study	  (Brown	  et	  al.	  2011),	  our	  schizophrenic	  
patients	   showed	   smaller	   gray	  matter	   volumes	   in	   the	   right	   hippocampus	  when	  
compared	   to	  bipolar	  patients;	  on	   the	  contrary,	  Brown	  et	  al.	  did	  not	   report	  any	  
hippocampal	  differences	  when	  bipolar	  subjects	  where	  compared	  to	  controls.	  
The	   significant	   results	   in	   our	   bipolar	   patients	   compared	   to	   controls	   might	   be	  
explained	  considering	  the	  patients’	  demographical	  and	  clinical	  variables.	  	  
First,	  global	  disease	  severity	  and	  functioning:	  as	  highlighted	  by	  the	  GAF	  scoring,	  
also	  the	  bipolar	  group	  suffered	  from	  moderate	  to	  serious	   illness	  with	  regard	  to	  
psychological,	   social	   and	   occupational	   functioning.	   Clinically,	   even	   if	   they	  were	  
assessed	  in	  a	  stable	  phase,	  most	  of	  them	  presented	  multiple	  mood	  episodes	  and	  
in	  some	  cases	  psychotic	  symptoms	  along	  the	  course	  of	  the	  disease;	  furthemore,	  
given	   the	   quite	   early	   age	   at	   onset,	   the	   presented	   sustained	   a	   long	   duration	  of	  
illness.	  	  
Some	   morphometric	   studies	   comparing	   psychotic	   bipolar	   patients	   to	   healthy	  
controls	  occasionally	  reported	  volumetric	  reductions	   in	  the	  subgenual	  cingulate	  
cortex	  (Hirayasu	  et	  al.	  1999)	  and	  left	  hippocampus	  (Velakoulis	  et	  al.	  1999).	  	  
In	   a	   longitudinal	   study,	   Moorhead	   and	   colleagues	   found	   that	   patients	   with	  
bipolar	  disorder	  showed	  a	  greater	  decline	   in	  hippocampal	  gray	  matter	  densisty	  
over	   4	   years	   than	   control	   subjects.	   Reductions	   in	   temporal	   lobe	   gray	   matter	  
correlated	   with	   the	   number	   of	   intervening	  mood	   episodes	   over	   the	   follow-­‐up	  
period	   (Moorhead	   et	   al.	   2007).	   These	   results	   imply	   that	   the	   decrease	   in	  
hippocampal	  volume	  in	  bipolar	  disorder	  may	  be	  depending	  on	  the	  severity	  of	  the	  
deseas.	   The	   previously	   cited	   article	   by	   Hajek	   at	   al.	   (2012)	   provide	   indirect	  
support	   for	   neuroprotective	   effects	   of	   Lithium	   but	   negative	   effects	   of	   illness	  
burden	  on	  hippocampal	  volumes	  in	  bipolar	  disorders.	  
Another	   possible	   confounder	   is	   education:	   the	   two	   patient	   groups	   had	  
comparable	   levels	   of	   education,	   	  	   but	   they	   showed	   significantly	   lower	   levels	   of	  
education	  than	  the	  healthy	  controls.	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Moreover,	  contradicting	  evidences	  and	  heterogeneity	   in	  structural	  MRI	  findings	  
in	   literature	   can	   be	   influenced	   by	   various	   factors	   including	   scan	   acquisition	  
parameters,	   image	   quality,	   hardware/software	   employed	   in	   the	   tracing	  
procedure	   and	   type	  of	   segmentation	   technique	   (manual	   or	   automatic)	   (Geuze,	  
Vermetten,	   and	   Bremner	   2005).	   It	   is	   currently	   not	   clear	  whether	   the	   negative	  
findings	   in	   the	   bipolar	   disorder	   literature	   are	   a	   result	   of	   sample	   selection,	  
medication	  biases,	  technical	  issues	  or	  represent	  a	  true	  biological	  pattern	  (Yüksel	  
et	  al.	  2012).	  
In	   the	   past	   years,	   given	   the	   difficulty	   to	   separate	   amygdala	   from	   the	  
hippocampus,	   the	  majority	  of	   studies	   combined	  amygdala	  and	  hippocampus	   in	  
the	   "amigdalo-­‐hippocampal	   complex"	   and	   then	   perform	   an	   approximate	  
separation,	   attributing	   the	   anterior	   part	   to	   amygdala	   and	   the	   rear	   part	   to	   the	  
hippocampus	  (Hirayasu	  et	  al.	  1998;	  Lawrie	  et	  al.	  1999).	  
It	   is	   possible	   that,	   in	   our	   study,	   better	   spatial	   resolution	   in	   the	   acquisition	   of	  
imaging	  data	  and	  the	  use	  of	  the	  stereological	  method	  are	  more	   likely	  to	  detect	  
discrete	   hippocampal	   atrophy.	   In	   fact,	   we	   obtained	   high	   coefficients	   of	   inter-­‐
rater	  and	  intra-­‐rater	  reliability,	  in	  the	  specific	  gray	  matter	  delimitation	  of	  Dentate	  
Gyrus,	  Cornu	  Ammonis	  and	  Subiculum;	  moreover,	  by	  using	  the	  “orthogonal”	  tool	  
we	   were	   able	   to	   work	   on	   three	   orthogonal	   perspectives	   simultaneously,	   thus	  
facilitating	   the	   delineation	   of	   difficult	   boundaries	   (e.g.,	   the	   transition	   of	   the	  
hippocampus	  to	  the	  amygdale	  in	  the	  anterior	  slices).	  
	  
The	   results	   from	   the	   comparison	   analysis	   between	   the	   unaffected	   first-­‐degree	  
relatives	   and	   the	   healthy	   control	   group	   are	   very	   interesting.	   We	   revealed	   a	  
statistically	  significant	  gray	  matter	  volume	  reduction	   in	  the	   left	  hippocampus,	  a	  
trend	   towards	   statistical	   significance	   for	   right	   hippocampus	   and	  no	   statistically	  
significant	  differences	   in	   total	  cerebral	  volumes	  between	  the	  groups;	  moreover	  
the	  trend	  towards	  statistically	  significant	  bilateral	  reduction	  in	  hippocampal	  gray	  
matter	  volumes	  persisted	  after	  normalization.	  
To	  date,	  there	  is	  no	  consensus	  about	  whether,	  and	  to	  what	  extent,	  gray	  matter	  
loss	   in	   Schizophrenia	   is	  mirrored	   in	   Bipolar	   Disorder	   and	  what	   is	   the	   effect	   of	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medication	  or	  other	  confounding	  factors.	  Studies	  in	  family	  members	  of	  patients,	  
who	   share	   the	   risk	   of	   the	   disease	   but	   not	   the	   confounding	   factors,	   may	   help	  
elucidate	  whether	  abnormalities	  in	  brain	  structures	  are	  shared	  by	  both	  illnesses.	  
In	   literature,	   hippocampal	   volume	   reductions	   and	   some	   other	   morphometric	  
deviations	   associated	  with	   schizophrenia	   have	   also	   been	   noticed	   in	   unaffected	  
first-­‐degree	  relatives	  of	  patients	  (Seidman	  et	  al.	  2002);	  a	  meta-­‐analysis	  of	  studies	  
comprising	   first-­‐degree	   relatives	  of	   schizophrenia	  patients	  and	  healthy	  controls	  
confirmed	  reductions	  in	  whole	  brain	  and	  hippocampus	  volume	  (Boos	  et	  al.	  2007).	  
By	   contrast,	   unaffected	   relatives	   of	   patients	   with	   bipolar	   disorder	   have	   been	  
rarely	   studied	   (McDonald	   et	   al.	   2006).	  A	   recent	  meta-­‐analysis	   (Fusar-­‐Poli	   et	   al.	  
2012)	   failed	   to	   detect	   significant	   differences	   in	   amygdala	   and	   hippocampal	  
volumes	  in	  individuals	  at	  high	  risk	  for	  bipolar	  disorder.	  However,	  results	  of	  meta-­‐
analysis	  should	  be	  interpreted	  with	  caution	  since	  conflicting	  data	  might	  also	  be	  a	  
consequence	  of	  heterogeneity	  across	  studies	  concerning	  different	  MRI	  scanners,	  
different	  acquisition	  protocols,	  small	  sample	  sizes	  and	  different	  inclusion	  criteria	  
for	  the	  high-­‐risk	  cohorts.	  
	  
The	   genetic	   inheritance	   of	   bipolar	   disorder	   and	   schizophrenia	   is	   complex:	   it	   is	  
most	   likely	   to	   be	   polygenic	   rather	   than	   due	   to	   genes	   of	   major	   effect.	   Since	  
unaffected	   relatives	   of	   patients	   with	   bipolar-­‐schizophrenic	   spectrum	   disorders	  
are	  likely	  to	  share	  some	  susceptibility	  genes	  with	  affected	  patients,	  without	  overt	  
expression	  of	  the	  clinical	  phenotype,	  structural	  abnormalities	  detectable	  in	  high-­‐
risk	   individuals	   but	   not	   in	   controls	   may	   reflect	   genetically	   driven	   trait-­‐related	  
deficits	  for	  the	  disorder.	  Sometimes	  the	  same	  abnormalities	  may	  also	  be	  evident	  
both	   in	   the	   unaffected	   and	   in	   the	   patient	   groups,	   suggesting	   the	   possibility	   of	  
genetic	  risk	  factors	  shared	  by	  both	  groups	  (Fusar-­‐Poli	  et	  al.	  2012).	  	  
Studying	  unaffected	  first-­‐degree	  relatives	  gives	  the	  advantage	  that	  the	  detected	  
abnormalities	   cannot	   be	   confounded	   by	   medication	   or	   other	   illness-­‐related	  
factors;	   conversely,	   studies	   of	   the	   unaffected	   relatives	   are	   limited	   by	   the	   fact	  
that	   they	   cannot	   discriminate	   between	   genetic	   and	   shared	   environmental	  
influence.	  Anyway,	  examination	  of	  the	  unaffected	  relatives	  of	  patients	  is	  a	  valid	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mean	   to	   study	   the	   relation	   between	   increased	   genetic	   risk	   and	   brain	  
abnormalities,	   since	   these	  people	  carry	   the	  genetic	   risk	   for	   the	  disease	  but	  not	  
the	   disease	   itself.	   In	   addition,	   studies	   in	   unaffected	   twins	   and	   first-­‐degree	  
relatives	   of	   probands	  might	   help	   to	   hypothesize	   putative	   endophenotypes	   for	  
such	   complex	   multifactorial	   disorders.	   Following	   Gottesman	   and	   Gould’s	  
rationale,	  the	  reasonable	  criteria	  for	  valid	  endophenotypes	  are	  the	  following:	  1)	  
the	   endophenotype	   is	   associated	   with	   illness	   in	   the	   population;	   2)	   the	  
endophenotype	   is	   heritable;	   3)	   the	   endophenotype	   is	   primarily	   state-­‐
independent	   (manifests	   in	   an	   individual	   whether	   or	   not	   illness	   is	   active);	   4)	  
within	  families,	  endophenotype	  and	  illness	  co-­‐segregate;	  5)	  the	  endophenotype	  
found	  in	  affected	  family	  members	  is	  found	  in	  non-­‐affected	  family	  members	  at	  a	  
higher	  rate	  than	  in	  the	  general	  population	  (Gottesman	  and	  Gould	  2003;	  Hasler	  et	  
al.	  2006;	  Braff	  et	  al.	  2007).	  
	  
Interpreting	   the	   results	   of	   our	   study,	   we	   should	   take	   into	   account	   some	  
limitations	  and	  confounding	  factors.	  First,	  for	  the	  patient	  group,	  we	  could	  not	  be	  
able	  to	  rule	  out	  the	  confounding	  factor	  of	  psychotropic	  medication,	  in	  particular	  
lithium	  and	  first-­‐	  or	  second-­‐generation	  antipsychotics.	  Second,	  the	  small	  sample	  
size	   of	   the	   unaffected	   relatives	   could	   limit	   the	   statistical	   power	   of	   our	  
comparison.	  
	  
In	   conclusion	   it	   might	   be	   speculated	   that	   the	   alterations	   of	   the	   gray	   matter	  
volume	   in	   the	  hippocampus	  highlighted	   in	  our	   study	   could	  be	   interpreted	  as	   a	  
possible	  structural	  “biological	  marker”	  in	  the	  schizophrenic-­‐bipolar	  spectrum.	  
Our	   future	   perspectives	   aim	   to	   increase	   the	   sample	   of	   unaffected	   first-­‐degree	  
relatives	   and	   to	   investigate	   possible	   correlations	   between	   the	   identified	  
structural	  alterations	  and	  polymorphisms	  of	  candidate	  genes	   (e.g.	  NTK3,	  BDNF,	  
COMT,	  GSK3),	   in	  order	   to	  verify	   the	  endophenotype	  hypothesis	  and,	   therefore,	  
the	  speculation	  of	  a	  common	  genetic	  substrate	  for	  the	  spectrum.	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